

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Peripartum care and obesity: A scoping review of recommendations and practical tools for implementation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061430
Article Type:	Original research
Date Submitted by the Author:	27-Jan-2022
Complete List of Authors:	Kominiarek, Michelle A. ; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Cassimatis, Irina; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Peace, Jack; Temple University Lewis Katz School of Medicine, Department of Anesthesiology Premkumar, Ashish ; Northwestern University, Obstetrics and Gynecology; John H Stroger Hospital of Cook County, Obstetrics and Gynecology Toledo, Paloma ; Northwestern University Feinberg School of Medicine, Anesthesiology O'Dwyer, Linda; Northwestern University, Obstetrics and Gynecology
Keywords:	OBSTETRICS, Maternal medicine < OBSTETRICS, PERINATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Title Page
4

5 Peripartum care and obesity: A scoping review of recommendations and practical tools
6
7 for implementation
8
9

10 Michelle A. KOMINIAREK, MD, MS¹ mkominia@nm.org
11

12 Irina CASSIMATIS, MD, MSc¹ irina.cassimatis@northwestern.edu
13

14 Jack M. PEACE, MD² jackpeace5@gmail.com
15

16 Ashish PREMKUMAR, MD^{1,3} ashish.premkumar@northwestern.edu
17

18 Paloma TOLEDO, MD, MPH⁴ p-toledo@northwestern.edu
19

20 Linda C. O'DWYER, MA, MSLIS⁵ l-odwyer@northwestern.edu
21

22
23
24 1 Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine,
25
26 Northwestern University Feinberg School of Medicine; Chicago, IL
27

28
29 2 Department of Anesthesiology, Temple University Lewis Katz School of Medicine;
30
31 Philadelphia, PA
32

33 3 Department of Obstetrics and Gynecology, John H Stroger Hospital; Chicago IL
34

35 4 Department of Anesthesiology, Northwestern University Feinberg School of Medicine;
36
37 Chicago, IL
38

39
40 5 Galter Health Sciences Library & Learning Center, Northwestern University Feinberg
41
42 School of Medicine; Chicago, IL
43

44
45 The scoping review protocol is published at <https://doi.org/10.18131/g3-gyms-ww23>.

46
47 (PROSPERO does not accept protocols for scoping reviews.)
48

49 This study will be presented in poster format at the Society for Maternal-Fetal Medicine
50
51 Annual Meeting in Orlando, Florida. January 31, 2022 - February 5, 2022.
52

53
54 Corresponding author:
55
56
57
58
59
60

Michelle A. Kominiarek, MD MS

Department of Obstetrics and Gynecology

Associate Professor, Northwestern University Feinberg School of Medicine

250 East Superior Street

Suite 05-2154

Chicago, IL 60611

(312)472-6747

mkominia@nm.org

Abstract word count 299

Main text word count 2929

For peer review only

Abstract

Objective: Despite the growing prevalence of obesity among reproductive aged persons in the U.S., evidence-based guidelines for peripartum care are lacking. The objective of this scoping review is to identify obesity-related recommendations for peripartum care, evaluate grades of evidence for each recommendation, and identify practical tools (e.g., checklists, toolkits, care pathways, bundles) to support their implementation in clinical practice.

Data sources: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from inception to December 2020 for eligible studies addressing peripartum care in persons with obesity.

Study eligibility criteria: Inclusion criteria were published evidence-rated recommendations and practical tools for peripartum care of persons with obesity.

Study appraisal and synthesis methods: Pairs of independent reviewers extracted data (source, publication year, content and number of recommendations, level and grade of evidence, description of tool) and identified similarities and differences among the articles.

Results: Of 18,315 screened articles, 18 were included including 7 articles with evidence-rated recommendations and 11 practical tools (3 checklists, 3 guidelines, 1 care bundle, 1 flowchart, 1 care pathway, 1 care map, 1 protocol). Thirteen of 39 evidence-rated recommendations were based on expert opinion. Recommendations related to surgical antibiotic prophylaxis and subcutaneous tissue closure at cesarean delivery received the highest-grade of evidence. Some of the practical tools included a

1
2
3 checklist from the United States regarding anticoagulation after cesarean delivery
4
5 (evidence supported recommendation), a bundle for surgical site infections after
6
7 cesarean delivery in Australia (evidence did not support recommendation), and a
8
9 checklist with content for several aspects of peripartum care from Canada (evidence
10
11 supported seven of nine definitive recommendations).
12
13
14

15 Conclusion: The recommendations for peripartum care for persons with obesity are
16
17 based on limited evidence and few practical tools for implementation exist. Future work
18
19 should focus on developing practical tools based on high quality studies.
20
21
22

23 Strengths and limitations of this study:
24

- 25
26 • We may not have identified all articles with evidence-rated recommendations,
27
28 though our search of available published literature was thorough including a
29
30 search of appropriate web sites.
31
32
- 33 • Sites may have practical implementation tools that they use in the short- or long-
34
35 term, but they may not be published or available in a more public domain.
36
37
- 38 • Although topics such as contraception and postpartum weight management are
39
40 important in the postpartum care of persons with obesity, they were not
41
42 specifically addressed in this review, which pertained to peripartum care in the
43
44 immediate postpartum period.
45
46
- 47 • We did not include recommendations that were intended for patient education
48
49 only in this review.
50
51

52
53 Keywords: obesity, peripartum care, pregnancy, tools
54
55
56
57
58
59
60

INTRODUCTION

Obesity has reached epidemic proportions in the United States.¹ In 2015-2016, 36.5% of reproductive age women (20-39 years) had obesity (BMI \geq 30.0 kg/m²), translating to a high percentage of persons with obesity during future pregnancies.² Of further concern, over 50% of persons with obesity exceed guidelines for weight gain during pregnancy, thus compounding their risks for adverse outcomes.³⁻⁵ Adverse peripartum outcomes associated with obesity include cesarean delivery, infection, hemorrhage, thromboembolism (VTE), and anesthesia-related complications, such as failure of regional anesthesia and respiratory depression.⁶ These adverse outcomes are amplified in persons with a BMI \geq 50 kg/m².⁷ Furthermore, obesity is cited as a contributing factor in over 50% of maternal deaths.⁸

Adaptations to prenatal care for persons with obesity include early screening for diabetes and limiting weight gain to 11-20 pounds. However, there is a lack of evidence-based recommendations for peripartum care, when the risk for adverse outcomes is a significant concern. For example, the National Institute for Health and Care Excellence (NICE) performed evidence-based reviews for the intrapartum management of obesity in 2019 and found no clinical evidence to suggest that the management of fetal monitoring or maternal positioning in labor should be altered.⁹

Strategies that have reduced adverse outcomes in obstetrics include the development of checklists or toolkits after identifying patient, provider, and systems factors for improvement in the care pathway.¹⁰ Given the increasing incidence of obesity and obesity-related complications, it is critical to identify opportunities to improve the safe delivery of peripartum care.

Objectives

The objective of this scoping review is to identify obesity-related recommendations for peripartum care, evaluate levels or grades of evidence for each recommendation, and identify practical tools such as checklists, toolkits, or other comprehensive care pathways to support their implementation in clinical practice.

METHODS

Eligibility criteria, information sources, search strategy

The PRISMA extension for scoping reviews (PRISMA-ScR) checklist was used in developing and reporting this scoping review.¹¹ The inclusion criteria were: (1) published (in print or online) recommendations along with levels or grades of evidence for the peripartum care of persons with obesity (BMI \geq 30.0 kg/m²), and if possible, specifically for persons with a BMI \geq 50 kg/m²; or (2) published (in print or online) description of a tool such as a checklist, toolkit, or comprehensive care pathway for the peripartum care of obesity. To be included in the review, the identified recommendations needed to focus on actionable items or management strategies, as opposed to being a listing of comorbidities or risks that are associated with obesity in pregnancy. Actionable items might include giving or withholding a particular medication or device. Recommendations that exclusively related to “patient counseling” or imparting of knowledge to the patient were not included as the interpretation of counseling can have different meanings depending on the clinical setting (e.g., location of clinical practice, provider type). The recommendations could have been abstracted from articles pertaining to obesity alone, or other articles that specified recommendations pertaining to obesity (e.g., antibiotic use in pregnancy with a specific adaptation for persons with obesity). Because

1
2
3 recommendations could be published from varying health care systems (e.g., national
4 guidelines from United States vs. United Kingdom), variances in evidence grading were
5 identified and abstracted according to the health care system's grading method.
6
7

8
9
10 We searched PubMed MEDLINE, Embase (embase.com), Cochrane Central Register
11 of Controlled Trials (Wiley), CINAHL (EbscoHost), and clinicaltrials.gov from inception
12 through December 2020, with no date or language restrictions. The search for eligible
13 studies involved controlled vocabulary (MeSH headings and thesauri of relevant
14 databases) and the keywords of obesity, morbid obesity, super morbid obesity,
15 guidelines, recommendations, checklist, toolkit, maternal care pathway, peripartum
16 care, and pregnancy. The bibliographies of relevant reviews were hand-searched, as
17 well as key websites including Google Scholar. A full list of the sources and search
18 strategies is outlined in Appendix A.
19
20
21
22
23
24
25
26
27
28
29
30

31 **Patient and Public Involvement**

32
33
34 Patients were not directly involved in the design of this study.
35
36

37 **Study Selection**

38
39 The questions for this scoping review were: (1) What are the recommendations for
40 peripartum care of persons with obesity published by either individual authors, national
41 societies, or other government departments that provide levels or grades of evidence to
42 support the recommendation? (2) What are the published tools for practical
43 implementation of recommendations, either in the form of checklists, toolkits, or other
44 comprehensive care pathways?
45
46
47
48
49
50
51

52
53 The primary outcomes were the number of recommendations per article, topic of
54 recommendation, level or grade of evidence to support recommendations, and
55
56
57
58
59
60

1
2
3 similarities and differences between the recommendations across articles. For the
4 identified checklists, toolkits, or other comprehensive care pathways for the peripartum
5 management of obesity, their details were summarized and crosschecked with the
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

similarities and differences between the recommendations across articles. For the identified checklists, toolkits, or other comprehensive care pathways for the peripartum management of obesity, their details were summarized and crosschecked with the aforementioned recommendations.

Data extraction

Four reviewers independently screened all citations using the Covidence review management software.¹² Initially, the reviewers were trained on a sample of 20 articles using the Covidence software to verify clarity and consistency regarding inclusion and exclusion criteria. A separate, 5th reviewer resolved all conflicts. Once agreement was obtained on articles meeting criteria for final inclusion, two reviewers independently extracted the following data from each article using a form that was tested and modified by the reviewers, as applicable: (1) source of recommendations (e.g., individual authors, national societies, etc.), (2) year of publication, (3) content and total number of recommendations, (4) level and grade of evidence for each of the recommendations, (4) system used to determine levels of evidence or classification of recommendations, (5) description of checklist, toolkit, comprehensive care pathway or other format used for implementation in the peripartum care of obesity. If articles were in abstract form only, we contacted the authors for updates on the status of the final publication.

Data synthesis

The data were summarized and abstracted into table format, noting key similarities and differences among the articles in terms of content and level and grade of evidence. For the identified checklists, toolkits, etc. similarities and differences among the content were highlighted. For this scoping review, we did not assess the effectiveness of the

1
2
3 findings or evaluate bias. The scoping review protocol is published at
4
5 <https://doi.org/10.18131/g3-gyms-ww23>.
6
7

8 **Ethics approval statement**

9

10 Ethics approval was not required since the study was a review of previously published
11
12 articles.
13
14

15 **RESULTS**

16 **Study selection**

17

18 After removal of duplicates, 18,328 articles were screened, resulting in 203 articles for
19
20 full-text review. Figure 1 shows the flow diagram for study selection. A total of 7
21
22 evidence-rated articles and 11 tools met inclusion criteria for this review. Eight of the
23
24 tools were selected from the results of Google Scholar searches.
25
26
27
28
29

30 **Study characteristics**

31

32 Table 1 displays the title, year of publication, source of recommendations, and
33
34 references for evidence levels and grades (n=7 articles) identified from the search of all
35
36 databases. For these articles, the content was either exclusively focused on the
37
38 management of obesity or the content was about a high-risk condition during pregnancy
39
40 and addressed obesity among other issues. Table 2 displays the topic, content of the
41
42 recommendation, and evidence levels and grades for each recommendation from the
43
44 seven articles in Table 1. For the tools, Table 3 displays the title, year of publication,
45
46 source of recommendations, and content topic for the peripartum management of
47
48 obesity identified from searches of PubMed MEDLINE, Embase, Cochrane Central
49
50 Register of Controlled Trials, and CINAHL (n=3). Appendix B displays the same
51
52 information identified from a search of key websites and Google Scholar for tools (n=8).
53
54
55
56
57
58
59
60

We found a wide range of tools including checklists, bundles, flow charts, guidelines, protocols, care pathways, and care maps from practices in the United States, Canada, and the United Kingdom.

Table 1. Title, year of publication, source of recommendations, evidence levels and grades for 7 articles related to peripartum management of obesity

Title	Date	Author/Source	Evidence Source
Management of prepregnancy, pregnancy, and postpartum obesity ¹³	2020	McAuliffe et al International Federation of Gynecology and Obstetrics	GRADE ¹⁴ Grade strong or weak Evidence low, moderate, high or best practice
SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery ¹⁵	2020	Society for Maternal-Fetal Medicine (United States); 1/6 recommendations pertain to obesity	GRADE ¹⁴ Grade strong or weak Evidence low, moderate, high or best practice
Guideline No. 247-Antibiotic prophylaxis in obstetric procedures ¹⁶	2017	J van Schalkwyk, N Van Eyk Society of Obstetricians and Gynaecologists of Canada (Canada); 1/7 recommendations pertain to obesity	Canadian Task Force on Preventive Health Care ¹⁷ Levels I-III Classifications A-I
Guideline No. 392- Pregnancy and maternal obesity Part 2: Team planning for delivery and postpartum care ¹⁸	2019, 2020 correction	Maxwell C, et al. Society of Obstetricians and Gynaecologists of Canada (Canada)	Canadian Task Force on Preventive Health Care ¹⁷ Levels I-III Classifications A-E,I
Care of women with obesity in pregnancy Green-top Guideline #72 ¹⁹	2018	Denison FC, et al. Royal College of Obstetricians and Gynaecologists (United Kingdom)	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines Levels 1++ to 4 Grades A-D, and "checkmark" ²⁰
Reducing the risk of venous thromboembolism during pregnancy and the puerperium Green-top Guideline No.37a ²¹	2015	Royal College of Obstetricians and Gynaecologists (United Kingdom)	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines Levels 1++ to 4 Grades A-D, and "checkmark" ²⁰
Practice Bulletin #156 Obesity in pregnancy ²²	2015	American College of Obstetricians and Gynecologists Practice Bulletin (United States)	U.S. Preventive Services Task Force Grade A-C; Levels I-III

GRADE Grading of Recommendations Assessment, Development and Evaluation

SMFM Society for Maternal-Fetal Medicine

RCOG Royal College of Obstetricians and Gynaecologists

Table 2. Topics, recommendations, and level or grade of evidence among 7 articles related to peripartum management of obesity.

Topic	Recommendation	Level or grade of evidence
Route of delivery	The decision for a woman with maternal obesity to give birth by planned caesarean section should involve a multidisciplinary approach, taking into consideration the individual woman's comorbidities, antenatal complications and wishes. ¹⁹	Level 2-, C
Labor induction	Induction of labor is recommended at 41+0 weeks of gestation for women with a BMI \geq 35 owing to their increased risk of intrauterine death. ¹³	Strong + + +
	Elective induction of labour at term in obese women may reduce the chance of caesarean birth without increasing the risk of adverse outcomes. ¹⁹	Level 2+, B
	Where macrosomia is suspected, induction of labour may be considered. Parents should have a discussion about the options of induction of labour and expectant management. ¹⁹	Level 1+, B
Fetal monitoring	Electronic fetal monitoring is recommended for women in active labor with a BMI \geq 35. Intrauterine pressure catheters and fetal scalp electrodes may help. ¹³	Conditional +
	(a) Electronic fetal monitoring can be considered for women in active labour with a body mass index $>$ 35 kg/m ² . (b) Intrauterine pressure catheters may assist in assessment of labour contractions. (c) Fetal scalp electrodes may be helpful to ensure continuous fetal monitoring when indicated. ¹⁸	III-B
Labor management	Allowing a longer first stage of labor before performing cesarean delivery for labor arrest should be considered in obese women. ²²	B, Level II-2,3
Blood pressure monitoring	Where available, an appropriately sized blood pressure cuff should be used for measurements. The cuff size used at the earliest time point should be documented in the medical records. ¹³	Conditional ++
IV access	Establish venous access in early labor for women with a BMI \geq 40 and consider a second cannula. ¹³	Conditional +
	Women with a BMI 40 kg/m ² or greater should have venous access established early in labour and consideration should be given to the siting of a second cannula. ¹⁹	Checkmark
Regional anesthesia	In the case of vaginal delivery for women with a BMI \geq 40, early placement of an epidural catheter is advisable in the case of an emergency cesarean delivery. ¹³	Conditional + +
Antibiotic prophylaxis for cesarean delivery	Women with a BMI \geq 30 having a cesarean delivery are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery. Women with obesity may benefit from higher doses. ¹³	Strong + + + +
	In patients with morbid obesity (BMI $>$ 35), doubling the antibiotic dose may be considered. ¹⁶	III-B
	Women with obesity may benefit from higher dosage of preoperative antibiotics for caesarean birth. ¹⁸	I-A
	Women with class 1 obesity or greater having a caesarean section are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery. ¹⁹	Level 1++, A
Incision type, skin closure for cesarean delivery	There is a paucity of high-quality evidence to support the use of one surgical approach over another. Surgical approaches should therefore follow NICE CG132 but clinicians may decide alternative approaches are merited depending on individual circumstances. ¹⁹	Checkmark
Subcutaneous tissue closure	It is recommended to reapproximate the subcutaneous tissue layers at the time of caesarean birth to reduce wound complications. ¹⁸	II-2A
	Women undergoing caesarean section who have more than 2 cm subcutaneous fat should have suturing of the subcutaneous tissue space in order to reduce the risk of wound infection and wound separation. ¹⁹	Level 1++, A

1			
2			
3		Subcutaneous drains increase the risk of postpartum cesarean wound complications and should not be used routinely. ²²	Grade A, Level 1
4		There is a lack of good-quality evidence to recommend the routine use of negative pressure dressing therapy, barrier retractors and insertion of subcutaneous drains to reduce the risk of wound infection in obese women requiring caesarean sections. ¹⁹	Level 2- to 1+, B
5			
6			
7	Hemorrhage	Active management of the third stage should be recommended to reduce the risk of postpartum hemorrhage. ¹³	Strong + + +
8		Although active management of the third stage of labour is advised for all women, the increased risk of PPH in those with a BMI greater than 30 kg/m ² makes this even more important. ¹⁹	Level 2++, A or Level 1++, B ^a
9			
10	VTE prophylaxis	Postoperative pharmacologic thromboprophylaxis should be prescribed based on maternal weight. ¹³	Conditional + +
11		Mechanical thromboprophylaxis is recommended before and after cesarean delivery. Where available, women with a BMI ≥ 35 should be given graduated compression stockings, or other interventions such as sequential compression devices, after cesarean delivery until mobilization, which should be encouraged early. ¹³	Conditional + +
12			
13			
14		When pharmacologic thromboprophylaxis is needed in pregnant women with class III obesity, we suggest the use of intermediate doses of enoxaparin [for cesarean delivery]. ¹⁵	2C
15			
16		Postoperative thromboprophylaxis is recommended, at appropriate dosing for the given body mass index due to the greater risk of venous thromboembolism following caesarean birth with women with obesity. ¹⁸	II-3 A
17			
18		All women with class 3 obesity (BMI greater than or equal to 40 kg/m ²) should be considered for prophylactic LMWH in doses appropriate for their weight for 10 days after delivery. ²¹	D
19			
20		Women with two or more persisting risk factors listed in Table 1 should be considered for LMWH in prophylactic doses appropriate for their weight for 10 days after delivery. One risk factor = BMI ≥ 30kg/m ² . ²¹	B
21			
22		Mechanical thromboprophylaxis is recommended before cesarean delivery, if possible, as well as after cesarean delivery. ²²	B, Level II-3
23		Weight-based dosage for venous thromboembolism thromboprophylaxis may be more effective than BMI-stratified dosage strategies in class III obese women after cesarean delivery. ²²	B, Level II-3
24			
25	Breastfeeding	Obesity is associated with low breastfeeding initiation and maintenance. Women with obesity in early pregnancy should receive specialist advice on the benefits of breastfeeding and appropriate antenatal and postnatal support for breastfeeding initiation and maintenance. ¹³	Conditional + +
26			
27		Women with obesity should be offered lactation support in the postpartum period. ¹⁸	III C
28			
29		Obesity is associated with low breastfeeding initiation and maintenance rates. Women with a booking BMI ≥ 30 kg/m ² or greater should receive appropriate specialist advice and support antenatally and postnatally regarding the benefits, initiation and maintenance of breastfeeding. ¹⁹	Checkmark, Level 1+
30			
31	Anesthesiology consult	Antenatal assessment with obstetric anaesthesia may assist in planning for safer birth for women with obesity. ¹⁸	III-A
32		The on-duty anaesthetist covering the labour ward should be informed of all women with class III obesity admitted to the labour ward for birth. This communication should be documented by the attending midwife in the notes. ¹⁹	Checkmark
33			
34	Systems	Where possible, healthcare facilities should have clearly defined pathways for the management of pregnant women with obesity. The adequacy of resources and equipment available should be considered when making decisions around care, especially for women with a BMI ≥ 40. ¹³	Conditional +
35			
36		Obstetric team planning may be helpful for women with obesity to navigate the steps in antenatal, labour and delivery, and postnatal care. ¹⁸	III-3 A ^b
37			
38		Consultation with anesthesia service should be considered for obese pregnant women with OSA because they are at an increased risk of hypoxemia, hypercapnia, and sudden death. ²²	C
39			
40			
41			
42			
43			
44			
45			
46			
47			

^a The recommendation is reports as “Level 2++, A” on page 26 of the document and also reported as “Level 1++, B” on pages 8 and 30 of the document.

^b The recommendation is reported as “III-3 A”, though this level and grade of evidence is not defined in the Society of Obstetricians and Gynaecologists of Canada document.

BMI body mass index

NICE CG National Institute for Health and Care Excellence Clinical Guidelines

VTE venous thromboembolism

PPH postpartum hemorrhage

IV intravenous

LMWH low molecular weight heparin

OSA obstructive sleep apnea

Table 3: Title, year of publication, source of recommendations, content topic, and evidence to support recommendation among 3 tools related to the peripartum management of obesity

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Title	Year	Source or Site	Tool type	Content	Evidence to support content when a definitive recommendation was made in the tool
Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery ²³	2020	Society for Maternal-Fetal Medicine	Checklist	VTE prophylaxis (after cesarean delivery) For women with body mass index (BMI) 40 kg/m ² or greater (class 3 obesity) who have thrombophilia or history of deep venous thrombosis or pulmonary embolism, intermediate-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg SC every 12 hours); continue for 6 weeks postoperatively	SMFM ¹⁵ Level C
Reducing surgical site infections post-cesarean section in an Australian hospital, using a bundled care approach ²⁴	2020	NSW Local Health District, Australia	Bundle	Subcutaneous tissue closure Negative pressure wound therapy BMI>35 (PICO) BMI > 40 (Prevena) applied in operating suite at the time of incision closure and left in-situ for 7 days	RCOG ¹⁹ Level to 1+, B does NOT support recommendation
Team Planning in Obstetrical Care for Women with Obesity ²⁵	2019	Mount Sinai Hospital in Toronto, Ontario Canada	Checklist	General admission for delivery PICC line recommended (checkbox) Intrapartum Type of delivery (spontaneous or induced labor or Cesarean delivery) (checkbox) Appropriate size [blood pressure] cuff Appropriate size gown, long monitoring belts Notify OB, Anesthesia, Respiratory therapist, Neonatology May need cross and type IUPC use (checkbox) Encourage ambulation Cesarean delivery Incision location	FIGO ¹³ Conditional ++ for BP cuff size RCOG ¹⁹ "Checkmark" for notify anesthesia

36/bmjopen-2022-011430 on 29 September 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

				<p>Method of [incision] closure</p> <p>Use of negative pressure wound system (checkbox).</p> <p>Plan for prolonged length of stay if OSA/CPAP (checkbox)</p> <p>Additional medication for gastric emptying/GERD and possible additional antibiotics</p> <p>Equipment (OR table with side bars and pads, OR tray, hover mat, epidural/spinal needle and portable ultrasound, Troop pillow, need for difficult airway try, Mobius retractor and Sturgeon, Traxi Panniculus retractor, negative pressure wound system)</p> <p>Need for increased length of stay due to anesthesia (checkbox) (e.g., CPAP for sleep apnea).</p> <p>Postpartum</p> <p>Bariatric bed required for a weight > 500 lbs. (check box)</p> <p>Delay in suture or staple removal with the postoperative day entered for removal as an outpatient.</p> <p>Prophylactic anticoagulation, early ambulation encouraged</p> <p>Pain management plan with dosage changes</p> <p>Breastfeeding, lactation consultant</p> <p>Dietician follow-up</p>	<p>SOGC^{16, 18} Level I-A and Level III-B for additional antibiotics</p> <p>FIGO¹³ Conditional 1+ for resources an equipment</p> <p>FIGO¹³ Conditional 1+ for resources an equipment</p> <p>None</p> <p>SMFM¹⁵ Level C, FIGO Conditional ++¹³, SOGC¹⁸ II-3 A, RCOG¹⁹ Grade B or D, ACOG²² Grade B Level II-3</p> <p>None</p> <p>FIGO¹³ Conditional ++, RCOG¹⁹ “checkmark”, Level 1+</p>
--	--	--	--	--	---

SMFM Society for Maternal-Fetal Medicine

BMI body mass index

SC subcutaneous

NSW North South Wales

36/bmjopen-2022-061430 on 19 September 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

RCOG Royal College of Obstetricians and Gynecologists

PICC peripherally inserted central catheter

BP blood pressure

OB obstetrics

IUPC intrauterine pressure catheter

OSA obstructive sleep apnea

CPAP continuous positive airway pressure

FIGO International Federation of Gynecology and Obstetrics

SOCG Society of Obstetricians and Gynaecologists of Canada

OR operating room

VTE venous thromboembolism

ACOG American College of Obstetricians and Gynecologists

For peer review only

Synthesis of Results

The evidence-rated recommendations covered topics such as labor induction (e.g., indication and timing), intravenous access, fetal monitoring (e.g., scalp electrodes, intrauterine pressure catheters), management of the 1st and 3rd stages of labor, breastfeeding, and system-related preparedness. Several recommendations were specific to cesarean delivery (e.g., incision type, antibiotic prophylaxis and dose, subcutaneous tissue closure, negative pressure dressings, and VTE prophylaxis) and anesthesia (e.g., consultation, early placement of an epidural catheter). In several instances, recommendations for persons with obesity did not differ from recommendations for persons without obesity (e.g., antibiotic prophylaxis for cesarean delivery).¹⁹ Three articles had one recommendation^{15, 16, 21} and the highest number of recommendations was 11 in a single article.¹³ The FIGO (International Federation of Gynecology and Obstetrics) Pregnancy and Non-Communicable Disease Committee published guidelines for the management of pre-pregnancy, pregnancy, and postpartum obesity. Their recommendations for peripartum management (n=11) were included in this analysis, but it should be noted that the recommendations were not unique to the article, but instead they were abstracted from previously published international articles.¹³

The recommendations that were of the highest grade (Strong, Level 1, or Grade A) were antibiotic prophylaxis for cesarean delivery,^{13, 19} higher dosage of preoperative antibiotics for cesarean delivery,^{16, 18} and subcutaneous tissue closure.^{19, 22} We noted that 13 recommendations were based on expert opinion or the lowest level of evidence. We noted that topics such as antibiotic prophylaxis (n=4 recommendations),^{13, 16, 18}

1
2
3 subcutaneous skin closure (n=4 recommendations),^{18, 19, 22} and VTE prophylaxis (n=8
4 recommendations)^{13, 15, 18, 22} were most commonly addressed. There were two instances
5
6 where a particular intervention was not recommended (e.g., subcutaneous drains,
7
8 negative pressure dressing therapy).^{19, 22} We did not find any recommendations that
9
10 directly opposed one other, but there were differences in the specifics of the
11
12 recommendations. For example, the American College of Obstetricians and
13
14 Gynecologists (ACOG) recommends an anesthesiology consult for persons with obesity
15
16 and obstructive sleep apnea whereas RCOG recommends that the anesthetist “be
17
18 informed of all women with class III obesity”.^{19, 22} In one guideline from the Society of
19
20 Obstetricians and Gynaecologists of Canada (SOGC), the recommendation is for a
21
22 “higher” dose¹⁸ and another recommendation from the SOGC is for a “double dose”¹⁶
23
24 of antibiotic prophylaxis. Regarding specific recommendations for persons with different
25
26 classes of obesity, we only found recommendations for weight-based VTE prophylaxis
27
28 dosing^{15, 21, 22} and anesthesiology consultations.¹⁹

29
30
31 Regarding the practical tools for implementation (Table 3), the style varied. In a
32
33 checklist and bundle, there were specific recommendations including “40 mg of
34
35 enoxaparin subcutaneously twice daily for VTE prophylaxis after cesarean delivery”²³
36
37 and “negative pressure wound therapy...applied in operating suite at the time of incision
38
39 closure and left-in-situ for 7 days”, respectively.²⁴ Another checklist had several
40
41 recommendations for intrapartum and postpartum care with check boxes (e.g.,
42
43 intrauterine pressure catheter use, incision type, negative pressure dressing therapy),
44
45 ultimately leaving the decision to perform the intervention or not up to the individual
46
47 provider.²⁵ Common terms found in the tools from Google Scholar searches included
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 “consider” a certain treatment option or “anticipate” a particular complication (Appendix
4 B). We noted differences in these tools for continuous fetal monitoring, where two tools
5 recommend continuous fetal monitoring,^{26, 27} but one did not.²⁸ In addition, two tools^{24,}
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29 recommended negative pressure dressing therapy for certain circumstances (e.g.,
BMI > 35 kg/m² or > 40 kg/m²) whereas another tool states “avoid the use of wound
vacs.”²⁶

We then evaluated the similarities and differences between the evidence-rated
recommendations in Table 2 and any of the published tools in Table 3. The evidence to
support or not support the content in the tools from Table 2 was provided in the last
column of Table 3. Some of the differences noted are as follows. The one
recommendation in the checklist from the Society for Maternal-Fetal Medicine was
supported from its own clinical series article.^{15, 23} The recommendation from the bundle
for prophylactic negative pressure wound therapy to reduce surgical site infection at a
hospital in New South Wales, Australia was not supported by any recommendations in
Table 2.²⁴ We observed that evidence-rated recommendations supported the majority
of the content in the checklist from Abdelmalek et al. These included to notify
anesthesiology providers, have resources available to accommodate increased weight
(e.g., operating room equipment, blood pressure cuffs), give prophylactic
anticoagulation (though dose adjustments not specified), and have a lactation
consultation.²⁵ However, content such as delay in staple removal or adjustments in
postpartum pain management were not found in other evidence-rated recommendations
in Table 2.

COMMENT

Principal Findings

In our scoping review of the peripartum management of obesity, we found seven articles with evidence-rated recommendations. The articles included national guidelines from the FIGO (n=11 recommendations), United States (n=6 recommendations), United Kingdom (n=13 recommendations), and Canada (n=9 recommendations). The majority of the levels of evidence were second or third tier (Level 2 from GRADE, Level II or III from Canadian Task Force on Preventive Health Care, or Grade B or C from US Preventive Services Task Force). The recommendation that was of the highest grade (Strong, Level 1 or Grade A) was antibiotic prophylaxis for cesarean delivery,^{13, 19} yet these recommendations apply to persons of all weights. A higher dosage of preoperative antibiotics for cesarean delivery also had the highest grade in one article¹⁸ as well as subcutaneous tissue closure.^{19, 22} We noted that 13 recommendations were based on expert opinion, or the lowest level of evidence.

Although we did not find directly opposing recommendations, there were subtle differences in some of the recommendations including anesthesia consults and antibiotic dosing. There is considerable debate over appropriate prophylactic dosing of antibiotics for cesarean delivery in persons with obesity given that pharmacokinetic studies suggest improved or similar tissue concentrations with adjusted dosing,³⁰⁻³³ whereas a study comparing clinical outcomes such as surgical site infections did not demonstrate significant differences when comparing standard vs. higher doses of antibiotics.³⁴ The variations in recommendations may reflect the uncertainty of whether to reach a physiological target vs. a clinical outcome.

Strengths and limitations in relation to other studies

1
2
3 A systematic review of guidelines available worldwide for the management of obesity in
4 pregnancy found 32 clinical practice guidelines covering the domains of preconception
5 care, care during pregnancy, diet and exercise during pregnancy, care immediately
6 before, during and after delivery, and postpartum care.³⁵ For delivery and postpartum
7 care, the authors identified the following recommendations: (1) obesity alone not an
8 indication for induction of labor, (2) early establishment of venous access during labor
9 for women with a BMI > 40 kg/m², (3) allowing for a longer 1st stage of labor before
10 performing a cesarean delivery for labor arrest, and (4) active management of the 3rd
11 stage of labor. Recommendations pertaining to cesarean delivery included: (1) obesity
12 alone not an indication for elective cesarean delivery, (2) need for adequate staffing and
13 equipment for maternal weight > 120 kg, (3) suturing subcutaneous tissue if > 2 cm of
14 depth, (4) use of mechanical thromboprophylaxis before and after cesarean delivery,
15 and (5) weight-based dosing of medication used to prevent VTE. Lastly, they also
16 identified recommendations for breastfeeding support and lactation consultants. These
17 recommendations were similar to the ones we identified from national guidelines in our
18 scoping review.^{18, 19, 22}

19
20
21 Several of the evidence-rated recommendations in Table 2 supported the content in the
22 11 tools we identified. However, we also found content not supported by evidence-rated
23 recommendations such as a peripherally inserted catheter for difficult intravenous
24 access and delayed staple removal. We identified a randomized controlled non-
25 inferiority trial of early (post-operative day 3) or delayed (between post-operative days 7
26 and 10) staple removal for transverse skin incisions in persons with a BMI ≥ 30 kg/m².³⁶
27
28 Although the study was stopped prior to reaching the targeted sample size, the
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 occurrence of superficial wound dehiscence was 15.2% in the early and 11.5% in the
4
5 delayed group (RR 1.3, 95% CI 0.7-2.4) and there were no other differences in the
6
7 secondary outcomes of seroma, hematoma, surgical site infection, or pain scores
8
9 among the two groups. Since the available evidence regarding timing of staple removal
10
11 is limited, other clinical and non-clinical characteristics such as provider and patient
12
13 preference likely contribute to decisions about staple removal timing. We found that the
14
15 recommendation for prophylactic negative pressure therapy in one tool contradicted the
16
17 Royal College of Obstetricians and Gynaecologists' recommendation regarding this
18
19 practice ("There is a lack of good-quality evidence to recommend the routine use of
20
21 negative pressure dressing therapy...").¹⁹ We acknowledge the content in the tools may
22
23 be unique to a site depending on available resources at the time of peripartum care as
24
25 well as historical practice patterns, cost, ease of use, and risk/benefit ratio to maternal
26
27 and fetal health. In the tools we reviewed, language such as "consider" or "anticipate"
28
29 suggests that a concrete recommendation is not available and care needs to be
30
31 individualized.
32
33
34
35
36
37

38 **Strengths and limitations of this study**

39
40 We acknowledge several limitations to our study. We may not have identified all articles
41
42 with evidence-rated recommendations, though our search of available published
43
44 literature was thorough including a search of appropriate web sites. Sites may have
45
46 practical implementation tools that they use in the short- or long-term, but they may not
47
48 be published or available in a more public domain. We identified clinical guidelines from
49
50 other countries including Ireland and Australia,^{37, 38} but they were not included in this
51
52 review because they were not accompanied by evidence-rated recommendations.
53
54
55
56
57
58
59
60

1
2
3 Although topics such as contraception and postpartum weight management are
4 important in the postpartum care of persons with obesity, they were not specifically
5 addressed in this review, which pertained to peripartum care in the immediate
6 postpartum period. Lastly, we did not include recommendations that were intended for
7 patient education only in this review.
8
9
10
11
12
13

14 **Meaning of the study**

15
16
17 Based on this scoping review, we propose the following key content for a peripartum
18 checklist or toolkit in Table 4. This content is based on evidence ratings and ease of
19 implementation. In summary, persons with obesity are at high risk for morbidity and
20 mortality, with an abundance of risk occurring during the peripartum period. Few
21 guidelines exist for the care of these persons and the evidence to support care is
22 limited. Thus, there is a need for high quality studies encompassing peripartum
23 interventions.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4: Proposed key content for a peripartum checklist or toolkit for persons with obesity

Content	Examples
Provider discussion on labor induction, delivery route, and labor management	Allow for longer labor Difficulties in fetal heart rate monitoring
Expert consultations	Anesthesiologists Lactation consultants
Prophylaxis for cesarean delivery	Mechanical devices for VTE prophylaxis Higher dose of antibiotic before delivery depending on BMI Higher dose of anticoagulant after delivery depending on BMI
Wound management	Close subcutaneous tissue without drains or wound therapy

Contributorship statement

MK designed the study protocol. LCO completed the database search of potential articles. MK, IC, JMP, AP, and PT reviewed abstracts, decided on inclusion and exclusion criteria, and reviewed the full-text of included articles. All authors contributed to the synthesis of results. All authors acknowledged approval of the final version for publication.

Competing interests

The authors have no competing interests to report.

Funding

There are no financial support resources to report.

Data sharing

The protocol is available for review at <https://doi.org/10.18131/g3-gyms-ww23>. A full list of the sources and search strategies is outlined in Appendix A.

REFERENCES

1. OGDEN CL, CARROLL MD, KIT BK, FLEGAL KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. *JAMA* 2014;311:806-14.
2. HALES CM, CARROLL MD, FRYAR CD, OGDEN CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief* 2017:1-8.
3. MOORE SIMAS TA, DOYLE CURIALE DK, HARDY J, JACKSON S, ZHANG Y, LIAO X. Efforts needed to provide Institute of Medicine-recommended guidelines for gestational weight gain. *Obstet Gynecol* 2010;115:777-83.
4. BODNAR LM, SIEGA-RIZ AM, SIMHAN HN, HIMES KP, ABRAMS B. Severe obesity, gestational weight gain, and adverse birth outcomes. *Am J Clin Nutr* 2010;91:1642-8.
5. DEPUTY NP, SHARMA AJ, KIM SY. Gestational Weight Gain - United States, 2012 and 2013. *MMWR Morb Mortal Wkly Rep* 2015;64:1215-20.
6. GUNATILAKE RP, PERLOW JH. Obesity and pregnancy: clinical management of the obese gravida. *Am J Obstet Gynecol* 2011;204:106-19.
7. MARSHALL NE, GUILD C, CHENG YW, CAUGHEY AB, HALLORAN DR. Maternal superobesity and perinatal outcomes. *Am J Obstet Gynecol* 2012;206:417 e1-6.
8. KNIGHT M NM, TUFFNELL D, SHAKESPEARE J, KENYON S, KURINCZUK JJ (EDS.). *Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-2015*. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2017. 2017.
9. National Institute for Health and Care Excellence Clinical Guidelines. Intrapartum care for women with existing medical conditions or obstetric complications and their babies. London, 2019.
10. BERNSTEIN PS, COMBS CA, Shields LE, Clark SL, Eppes CS. The development and implementation of checklists in obstetrics. *Am J Obstet Gynecol* 2017;217:B2-B6.
11. TRICCO AC, LILLIE E, ZARIN W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169:467-73.
12. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
13. McAULIFFE FM, KILLEEN SL, JACOB CM, et al. Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: A FIGO (International Federation of Gynecology and Obstetrics) guideline. *Int J Gynaecol Obstet* 2020;151 Suppl 1:16-36.
14. GUYATT GH, OXMAN AD, VIST GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
15. PACHECO LD, SAADE G, METZ TD. Society for Maternal-Fetal Medicine Consult Series #51: Thromboembolism prophylaxis for cesarean delivery. *Am J Obstet Gynecol* 2020;223:B11-B17.
16. VAN SCHALKWYK J, VAN EYK N. No. 247-Antibiotic Prophylaxis in Obstetric Procedures. *J Obstet Gynaecol Can* 2017;39:e293-e99.

17. CANADIAN TASK FORCE ON PREVENTIVE HEALTH C. New grades for recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ* 2003;169:207-8.
18. MAXWELL C, GAUDET L, CASSIR G, et al. Guideline No. 392-Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care. *J Obstet Gynaecol Can* 2019;41:1660-75.
19. DENISON FC, AEDLA NR, KEAG O, et al. Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72. *BJOG* 2019;126:e62-e106.
20. Royal College of Obstetricians and Gynaecologists. Developing a Green-top Guideline: Guidance for developers. London: RCOG, 2020.
21. RCOG. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. April 2015.
22. ACOG Practice Bulletin No 156: Obesity in Pregnancy. *Obstet Gynecol* 2015;126:e112-e26.
23. COMBS CA. Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery. *Am J Obstet Gynecol* 2020;223:B22-B23.
24. BOLTE M, KNAPMAN B, LEIBENSON L, BALL J, GILES M. Reducing surgical site infections post-caesarean section in an Australian hospital, using a bundled care approach. *Infect Dis Health* 2020;25:158-67.
25. ABDELMALEK MZ, GUEST S, MAXWELL C. Team Planning in Obstetrical Care for Women With Obesity. *J Obstet Gynaecol Can* 2019;41:338-43.
26. University of New Mexico School of Medicine. Standard operating procedure-guideline class 3 obesity and pregnancy. 2020. Available from: <http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf>
27. Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg>.
28. Obesity in pregnancy guidelines: Northern Devon Healthcare NHS Trust, 2020.
29. Antenatal management of obesity: Spectrum Health The Medical Group Maternal Fetal Medicine; 2018. Available from: www.spectrumhealth.org/mfm/protocol-obesity.
30. KRAM JJF, GREER DM, CABRERA O, BURLAGE R, FORGIE MM, SIDDIQUI DS. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? *Eur J Obstet Gynecol Reprod Biol* 2017;210:334-41.
31. YOUNG OM, SHAIK IH, TWEDT R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. *Am J Obstet Gynecol* 2015;213:541 e1-7.
32. MAGGIO L, NICOLAU DP, DACOSTA M, ROUSE DJ, HUGHES BL. Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. *Obstet Gynecol* 2015;125:1205-10.
33. GRUPPER M, KUTI JL, SWANK ML, MAGGIO L, HUGHES BL, NICOLAU DP. Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight

- 1
2
3 and Obese Women Undergoing Cesarean Delivery. *J Clin Pharmacol* 2017;57:712-19.
4
5 34. AHMADZIA HK, PATEL EM, JOSHI D, et al. Obstetric Surgical Site Infections: 2
6 Grams Compared With 3 Grams of Cefazolin in Morbidly Obese Women. *Obstet*
7 *Gynecol* 2015;126:708-15.
8
9 35. SIMON A, PRATT M, HUTTON B, et al. Guidelines for the management of pregnant
10 women with obesity: A systematic review. *Obes Rev* 2020;21:e12972.
11 36. NUTHALAPATY FS, LEE CM, LEE JH, KUPER SG, HIGDON HL, 3RD. A randomized
12 controlled trial of early versus delayed skin staple removal following caesarean
13 section in the obese patient. *J Obstet Gynaecol Can* 2013;35:426-33.
14 37. Institute of Obstetricians and Gynaecologists Royal College of Physicians of
15 Ireland. Obesity and Pregnancy Clinical Practice Guideline. Guideline No.2 June
16 2011, revised June 2013.
17 38. The Australian and New Zealand College of Obstetricians and Gynaecologists.
18 C-Obs 49 Management of Obesity in Pregnancy. 2013.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Figure 1: PRISMA flow diagram for study selection.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1

176x196mm (96 x 96 DPI)

Appendix A Search Strategy

PubMed MEDLINE

Guidelines search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient[tiab] OR Parturients[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab]) AND (Toolkit[tiab] OR toolkits[tiab] OR Guideline[tiab] OR guidelines[tiab] OR Recommend*[tiab] OR Checklist[tiab] OR checklists[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR "Best practice"[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR "Network Meta-Analysis"[Mesh] OR systematic[ti] OR scoping[ti] OR meta-analy*[ti])

Interventions search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient*[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab])

AND (Toolkit*[tiab] OR Guideline*[tiab] OR Recommend*[tiab] OR Checklist*[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR Best practice*[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Early Medical Intervention"[Mesh] OR "Patient Education as Topic"[Mesh] OR "Health Education"[Mesh] OR intervention*[tiab] OR therapy[subheading] OR therapy[tiab] OR treatment[tiab])

AND

("Case-Control Studies"[Mesh:noexp] OR "retrospective studies"[mesh:noexp] OR "Control Groups"[Mesh:noexp] OR (case[TIAB] AND control[TIAB]) OR (cases[TIAB] AND controls[TIAB]) OR (cases[TIAB] AND controlled[TIAB]) OR (case[TIAB] AND comparison*[TIAB]) OR (cases[TIAB] AND comparison*[TIAB]) OR "control

group"[TIAB] OR "control groups"[TIAB] OR cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] OR randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh]))

Filters used for the interventions search:

http://libguides.sph.uth.tmc.edu/search_filters/pubmed_filters

<https://work.cochrane.org/pubmed>

Embase (embase.com)

Guidelines search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'evidence based practice'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR Toolkit*:ti,ab OR Guideline*:ti,ab OR Recommend*:ti,ab OR Checklist*:ti,ab OR consensus:ti,ab OR Evidence-based:ti,ab OR 'Best practice*':ti,ab OR "Clinical management":ti,ab OR "Anesthetic management":ti,ab OR anesthesia:ti,ab OR anaesthesia:ti,ab OR Standards:ti,ab OR systematic:ti OR scoping:ti OR meta-analy*:ti

Interventions search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR toolkit*:ti,ab OR guideline*:ti,ab OR recommend*:ti,ab OR checklist*:ti,ab OR consensus:ti,ab OR 'evidence based':ti,ab OR 'best practice':ti,ab OR 'clinical management':ti,ab OR 'anesthetic management':ti,ab OR standards:ti,ab OR 'intervention study'/exp OR 'patient education'/exp OR 'health education'/exp OR 'therapy'/exp OR intervention*:ti,ab OR therapy:ti,ab OR treatment:ti,ab

AND

'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind procedure':de OR (random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* NEAR/1 blind* OR assign* OR allocat* OR volunteer*):de,ab,ti OR 'clinical article'/exp OR 'controlled study'/exp OR 'major clinical study'/exp OR 'prospective study'/exp OR 'cohort analysis'/exp OR 'cohort':ti,ab OR 'compared':ti,ab OR 'groups':ti,ab OR 'case control':ti,ab OR 'multivariate':ti,ab

Filters:

<https://guides.library.harvard.edu/c.php?g=309982&p=2079546>

<https://work.cochrane.org/embase>

CENTRAL: Cochrane Register of Controlled Trials

Guidelines and intervention search

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 (Obesity OR Obese OR Superobesity):ti,ab,kw

- 1
2
3 #3 #1 OR #2
4
5 #4 MeSH descriptor: [Pregnancy] explode all trees
6
7 #5 MeSH descriptor: [Pregnancy Complications] explode all trees
8
9 #6 MeSH descriptor: [Pregnant Women] explode all trees
10
11 #7 MeSH descriptor: [Delivery, Obstetric] explode all trees
12
13 #8 MeSH descriptor: [Peripartum Period] explode all trees
14
15 #9 MeSH descriptor: [Perinatal Care] explode all trees
16
17 #10 Pregnancy:ti,kw,ab OR Pregnancies:ti,kw,ab OR Pregnant:ti,kw,ab OR
18 Parturition:ti,kw,ab OR Parturient*:ti,kw,ab OR Peripartum:ti,kw,ab OR Perinatal:ti,kw,ab
19 OR Prenatal:ti,kw,ab OR Antenatal:ti,kw,ab OR Antepartum:ti,kw,ab OR
20 Intrapartum:ti,kw,ab OR Postpartum:ti,kw,ab OR Cesarean:ti,kw,ab
21
22 #11 {OR #4-#10}
23
24 #12 Toolkit*:ti,kw,ab OR Guideline*:ti,kw,ab OR Recommend*:ti,kw,ab OR
25 Checklist*:ti,kw,ab OR consensus:ti,kw,ab OR Evidence-based:ti,kw,ab OR Best
26 practice*:ti,kw,ab OR “Clinical management”:ti,kw,ab OR “Anesthetic
27 management”:ti,kw,ab OR anesthesia:ti,kw,ab OR anaesthesia:ti,kw,ab OR
28 Standards:ti,kw,ab
29
30
31 #13 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
32
33 #14 systematic:ti OR scoping:ti OR meta-analy*:ti
34
35 #15 #12 OR #13 OR #14
36
37 #16 #3 AND #11 AND #15
38
39 #17 MeSH descriptor: [Early Medical Intervention] explode all trees
40
41 #18 MeSH descriptor: [Patient Education as Topic] explode all trees
42
43 #19 MeSH descriptor: [Health Education] explode all trees
44
45 #20 MeSH descriptor: [Therapeutics] explode all trees
46
47 #21 intervention*:ti,kw,ab OR therapy:ti,kw,ab OR treatment:ti,kw,ab
48
49 #22 {OR #17-#21}
50
51 #23 #3 AND #11 AND #22
52
53 #24 #16 OR #23
54
55
-

CINAHL (EbscoHost)

Guidelines search

((MH "Obesity") OR (MH "Obesity, Morbid")) OR TI (Obesity OR Obese OR Superobesity) OR AB (Obesity OR Obese OR Superobesity)

AND

((MH "Pregnancy+") OR (MH "Pregnancy, Multiple+") OR (MH "Pregnancy Trimesters+") OR (MH "Pregnancy, Unplanned") OR (MH "Pregnancy, Unwanted") OR (MH "Expectant Mothers") OR (MH "Pregnancy Complications+") OR (MH "Obstetric Care+") OR (MH "Postnatal Care+") OR (MH "Postnatal Period+")) OR TI (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean) OR AB (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean)

AND

((MH "Practice Guidelines") OR (MH "Meta Analysis") OR (MH "Meta Synthesis")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR TI (systematic OR scoping OR meta-analy*)

Interventions search

((MH "Early Intervention") OR (MH "Patient Education+") OR (MH "Health Education+") OR (MH "Pregnancy Outcomes") OR (MH "Treatment Outcomes+")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment)

AND

(MH "Prospective Studies") OR TI (cohort OR longitudinal OR prospective OR retrospective) OR AB (cohort OR longitudinal OR prospective OR retrospective) OR ((MH "Random Assignment") or (MH "Random Sample+") or (MH "Crossover Design") or (MH "Clinical Trials+") or (MH "Comparative Studies") or (MH "Control (Research)+") or (MH "Control Group") or (MH "Factorial Design") or (MH "Quasi-Experimental Studies+") or (MH "Placebos") or (MH "Meta Analysis") or (MH "Sample Size") or (MH "Research, Nursing") or (MH "Research Question") or (MH "Research Methodology+") or (MH "Evaluation Research+") or (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") or (MH "Nursing Practice, Research-Based") or (MH "Solomon Four-Group Design") or (MH "One-Shot Case Study") or (MH "Pretest-Posttest Design+") or (MH "Static Group Comparison") or (MH "Study Design") or (MH "Clinical Research+")) or (clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or meta?analy* or systematic review* or blind* or mask* or trial*))

Clinicaltrials.gov

Keyword searches included pregnancy and obesity.

Google searches

Recognizing that guidelines, toolkits, and checklists are often not published in the journal literature, we supplemented the guidelines search strategy with Google searches. To ensure more precision we limited the results to .org and .gov domains.

Searches were run in Google for "obesity pregnancy guideline" with the following limits:

1. Words in page title only
2. Words in URL only
3. .org domain
4. .gov domain
5. .gov.uk domain
6. .org.uk domain
7. .gov.au domain
8. .org.au domain

On the assumption that the Google search algorithm pushes the most relevant results to the top, one reviewer (MK) screened the first four pages of results for each search, looking for guidelines and checklists not already included in our previous search results. For the identified sites, the other authors (PT, AP, IC, JP) also voted to include or exclude the sites. The most recent search was conducted in April 2021.

Title	Year	Source or Site	Tool type	Content
Obesity in Pregnancy ^{1 a}	8.2021	Department of Health in Queensland, AU Guideline: Obesity and pregnancy (including post bariatric surgery) (health.qld.gov.au)	Flow Chart	<p>Intrapartum</p> <p>If BMI > 40 kg/m²</p> <ul style="list-style-type: none"> Early assessment of IV access Recommend continuous fetal monitoring <p>If prophylactic antibiotics, consider higher dosage</p> <p>Active third stage management</p> <p>Surveillance for shoulder dystocia/PPH</p> <p>Postpartum</p> <ul style="list-style-type: none"> Surveillance for airway compromise Early mobilisation Assess risk of VTE and consider thromboprophylaxis Additional support for breastfeeding
Class 3 Obesity and Pregnancy ²	7.2020	University of New Mexico Department of Obstetrics and Gynecology http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%20and%20Obesity%20and%20Pregnancy.pdf	Standard operating procedure-guideline	<p>Intrapartum</p> <ul style="list-style-type: none"> No clear evidence for routine IOL solely for class 3 obesity Higher morbidity with TOLAC compared to repeat CD in this specific population Consider repeat CD in this population Alert team of increased risk of shoulder dystocia and PPH Anesthesia evaluation before admission, or early in admission Pneumatic compression stockings during labor Continuous fetal and uterine monitoring in labor Avoid use of wound vacs or drains <p>Postpartum</p> <ul style="list-style-type: none"> Low-molecular weight heparin for thromboprophylaxis for 5-6 days postpartum Weight based prophylaxis is better option Breast feeding encouraged due to higher risks of difficulties Lactation counseling Consider lactation consulting Incentive spirometry Early ambulation Avoid early hospital discharge
Obesity in Pregnancy ³	4.2018	Alaska Native Medical Center https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf	Guideline	<p>Intrapartum</p> <ul style="list-style-type: none"> Use appropriate sized blood pressure cuff Anticipate higher dose of oxytocin for induction or augmentation of labor Consider placement of prophylactic epidural catheter <p>If BMI > 40 kg/m²</p> <ul style="list-style-type: none"> Consider early IUPC and FSE

36/bmjopen-2022-061433 Downloaded from <http://bmjopen.bmj.com/> on April 20, 2022 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

				<p>If BMI > 50 kg/m² Anesthesia consult on admission Consider additional use of IV famotidine and/or metoclopramide Anticipate higher rate of failed regional anesthesia Anticipate difficult airway (have videolaryngoscope available, have laryngeal mask airway available, have emergency cricothyroidotomy kit available) If Cesarean delivery Bariatric surgery should not be considered an indication for CD Anticipate greater time from incision to delivery Pfannenstiel incision carries less risk of infection and dehiscence than midline incision Consider retracting panniculus cephalad (or caudad) with tape or large “loban” drape Consider self-retaining retractor, extra-long instruments Close subcutaneous layer (34% decrease in wound disruption) Subcutaneous drains may be associated with a higher risk of infection Consider closure with polydioxanone (PDS) Consider Smead-Jones “mass closure” If staples used for skin closure, do not remove until 7-10 days postoperatively for a vertical incision and 5 days for a Pfannenstiel Increase dose of prophylactic cefazolin to 3 g IV before incision if BMI > 40 kg/m² Panniculectomy at the time of CD increases complications Early ambulation Intermittent pneumatic compression devices Consider using bariatric bed with frame and trapeze for mobility postoperatively Anticoagulation if 1 major or 2 minor ACP risk factors for VTE Enoxaparin 40mg every 12 hours for BMI < 50 kg/m², 60 mg every 12 hours for BMI > 50 kg/m² or weight based dosing (e.g., enoxaparin 0.5 mg/kg every 12 hours)</p>
Obesity in Pregnancy Guideline ⁴	9.2020	National Health System Northern Devon Healthcare United Kingdom https://www.northdevo	Care Pathway	<p>Intrapartum All blood pressure measurements should be taken using the appropriate size arm cuff. Complete a manual handling risk assessment to ensure the correct equipment is available and used</p>

		<p>nhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf</p>		<p>Measure and fit TED anti-embolism stockings. Consider calf compression device for all women with BMI ≥ 40. Assess pressure areas and maintain skin integrity. Consider ultrasound scan to confirm fetal presentation. Be alert to increased risk of shoulder dystocia. The duty anaesthetist and duty obstetric registrar should be informed when a woman with a BMI ≥ 40 is admitted to labour ward. Women with a BMI ≥ 40 should have IV access early in labour with "FBC and group and save taken". For women with a BMI ≥ 40, prophylactic omeprazole should be administered as per prescription. Raised BMI alone is not an indication for continuous fetal monitoring in labour. Postpartum All women with a BMI ≥ 35 should be recommended to have active management of the third stage of labour Women with a BMI ≥ 30 should be encouraged to mobilise as early as practicable following childbirth to reduce the risk of thromboembolism. TED stockings or calf compression devices to be worn throughout hospital stay regardless of mode of delivery for women with BMI ≥ 35. Assess wound and observe for signs of dehiscence.</p>
<p>Obesity in Pregnancy, Labour and Puerperium ⁵</p>	<p>2019</p>	<p>University Hospitals of Leicester NHS Trust United Kingdom Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk)</p>	<p>Guideline</p>	<p>Intrapartum: Assessment of tissue viability by completing "Waterlow Risk Assessment Form"; if value > 10 then inspect skin daily via "BEST SHOT" guidance (also postpartum) Notify OR staff on admission if weight > 140 kg Postpartum: Early mobilization Use compression stocking if ≥ 2 risk factors VTE prophylaxis for 7 days if ≥ 1 risk factors If BMI ≥ 40: Early IV access Consider early epidural Experienced obstetrician (\geq ST6) to perform CD or "rotational instrumental delivery" Active management of 3rd stage Consider IV syntocinon instead of IM route</p>

36/bmjopen-2022-011330 on 15 September 2022. Downloaded from <http://bmjopen.bmj.com/> on 15 September 2022. Protected by copyright.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

36/bmjopen-2022-014800 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on 19 April 2024 by guest. Protected by copyright.

				VTE prophylaxis regardless of delivery route Consider increased dose of antibiotic prophylaxis
Obesity Medicine Management of obesity in women's health care. Chapter 19: Checklists for Care: Care Maps for Pregnancy in the Obese Gravida ⁶	2017	United States	CareMap	Intrapartum Obtain clear fetal heart tracing and uterine contraction assessment Place SCD Early consultation with anesthesia Confirm adequate equipment for anesthesia, labor and delivery, and operating room Discuss/plan for the following: delivery route, skin cleansing/preparation, antibiotic dosing for CD (consider 3g cefazolin if weight > 120 kg), postpartum VTE prophylaxis (SCD, LMWH), early ambulation, perineal laceration or incision care, address medical comorbidities, medication adjustments Immediate postpartum VTE prophylaxis Early ambulation Anticoagulation (if indicated) Lactation referral
Supporting a Plus-Size Pregnancy: A Checklist for Healthcare Providers ⁷	2019	United States NIH/NICHD, National Child and Maternal Health Education Program NIH Pub.Number: 19-HD-8100 https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf	Checklist	Ensure availability of appropriate birthing beds and monitoring/other equipment to care for plus-size patients (e.g., large chairs and wheelchairs, larger blood pressure cuffs). Assess appropriateness of gurneys and staffing plans and revise as needed (e.g., get motorized lifts for gurneys, increase staff to assist with moving the patient). Consider consulting with an anesthesia service, especially for patients with obstructive sleep apnea, in case the need for a surgical delivery arises. Consider early epidural catheter placement, and discuss the risks and benefits with the patient. Consider allowing a longer first stage of labor before performing cesarean delivery for labor arrest. Work with your patient to create a birthing plan, including pain management methods. Work with your patient to create a breastfeeding plan and help her get lactation support/consultation, if needed.
Antenatal Management of Obesity ⁸	2018	Spectrum Health Medical Group Michigan, United States	Protocol	Anesthesia consult if BMI > 60 Prophylactic antibiotics "Azithro + Ancel" (3g if >120kg) Delivery timing 39-40 weeks

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		www.spectrumhealth.org/mfm/protocol-obesity		Consider wound vac placement post op if Class III obesity with risk factors (DM, chorio) or BMI > 60 Postop prophylactic lovenox while inpatient for class I and II obesity with risk factors, >= class III regardless of risk factors
--	--	--	--	---

Appendix B: Title, year of publication, source of recommendations, and content topic for tools for the peripartum management of obesity identified from searches of Google Scholar.

^a During original Google scholar search on 4.1.21, the Queensland Clinical Guideline for “Obesity in pregnancy” was published in 2015. When the manuscript was updated for publication, a new version of the guideline was published in 8.2021 and therefore the most recent guideline was used for this manuscript since the prior link was no longer available.

IOL induction of labor

CD or CS cesarean delivery

IV intravenous

BMI body mass index

PPH postpartum hemorrhage

VTE venous thromboembolism

TOLAC trial of labor after cesarean

IUPC intrauterine pressure catheter

FSE fetal scalp electrode

PDS polydioxanone

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

ACCP American College of Chest Physicians

TED thrombo-embolus deterrent

OR operating room

NIBP non-invasive blood pressure

BP blood pressure

NB neuraxial blockade

LMWH low molecular weight heparin

DM diabetes

For peer review only

Reference List for Appendix B

1. Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg> Accessed 9/24/21.
2. Gynecology UoNMSoMDoOa. Standard operating procedure-guideline class 3 obesity and pregnancy <http://unmobgyn.pbworks.com/w/file/fetch/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf> 2020 [
3. Obesity in pregnancy - ANMC guideline Alaska Native Medical Center [Available from: <https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf>
4. Obesity in pregnancy guideline National Health System Northern Devon Healthcare2020 [Available from: <https://www.northdevonhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf>.
5. Obesity in pregnancy, labour and the puerperium University Hospitals of Leicester NHS Trust2019 [Available from: Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk).
6. RK S. Obesity Medicine: Management of Obesity in Women's Health Care 1ed: McGraw-Hill Education; 2017.
7. Supporting a plus-size pregnancy: a checklist for healthcare providers NIH Pub.Number: 19-HD-8100: Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2019 [Available from: https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf.
8. Antenatal management of obesity: Spectrum Health The Medical Group Maternal Fetal Medicine; 2018 [Available from: www.spectrumhealth.org/mfm/protocol-obesity.

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	3
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Cover letter
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	4
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	4, Appendix A
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix A
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	4
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	5
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	5



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	5
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	5, figure 1
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	6, Table 1,2,Appendix B
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	6-7
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	6-7
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	8
Limitations	20	Discuss the limitations of the scoping review process.	10
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	9, Table 3
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Title page

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: 10.7326/M18-0850.



St. Michael's

Inspired Care.
Inspiring Science.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Peripartum care of persons with obesity: A scoping review of recommendations and practical tools for implementation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061430.R1
Article Type:	Original research
Date Submitted by the Author:	12-Aug-2022
Complete List of Authors:	Kominiarek, Michelle A. ; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Cassimatis, Irina; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Peace, Jack; Temple University Lewis Katz School of Medicine, Department of Anesthesiology Premkumar, Ashish ; Northwestern University, Obstetrics and Gynecology; John H Stroger Hospital of Cook County, Obstetrics and Gynecology Toledo, Paloma ; Northwestern University Feinberg School of Medicine, Anesthesiology O'Dwyer, Linda; Northwestern University, Obstetrics and Gynecology
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Evidence based practice
Keywords:	OBSTETRICS, Maternal medicine < OBSTETRICS, PERINATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Title Page
4

5 Peripartum care of persons with obesity: A scoping review of recommendations and
6
7 practical tools for implementation
8
9

10 Michelle A. KOMINIAREK, MD, MS¹ mkominia@nm.org
11

12 Irina CASSIMATIS, MD, MSc¹ irina.cassimatis@northwestern.edu
13

14 Jack M. PEACE, MD² jackpeace5@gmail.com
15

16 Ashish PREMKUMAR, MD^{1,3} ashish.premkumar@northwestern.edu
17

18 Paloma TOLEDO, MD, MPH⁴ p-toledo@northwestern.edu
19

20 Linda C. O'DWYER, MA, MSLIS⁵ l-odwyer@northwestern.edu
21

22
23
24 1 Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine,
25
26 Northwestern University Feinberg School of Medicine; Chicago, IL
27

28
29 2 Department of Anesthesiology, Temple University Lewis Katz School of Medicine;
30
31 Philadelphia, PA
32

33 3 Department of Obstetrics and Gynecology, John H Stroger Hospital; Chicago IL
34

35 4 Department of Anesthesiology, Northwestern University Feinberg School of Medicine;
36
37 Chicago, IL
38

39
40 5 Galter Health Sciences Library & Learning Center, Northwestern University Feinberg
41
42 School of Medicine; Chicago, IL
43

44 The scoping review protocol is published at <https://doi.org/10.18131/g3-gyms-ww23>.
45

46 (PROSPERO does not accept protocols for scoping reviews.)
47

48
49 This study was presented in poster format at the Society for Maternal-Fetal Medicine
50
51 Annual Meeting in Orlando, Florida. January 31, 2022 - February 5, 2022.
52

53
54 Corresponding author:
55
56
57
58
59
60

Michelle A. Kominiarek, MD MS

Department of Obstetrics and Gynecology

Associate Professor, Northwestern University Feinberg School of Medicine

250 East Superior Street

Suite 05-2154

Chicago, IL 60611

(312)472-6747

mkominia@nm.org

Abstract word count 299

Main text word count 3238

For peer review only

Abstract

Objective: Despite the growing prevalence of obesity among reproductive aged persons in the U.S., evidence-based guidelines for peripartum care are lacking. The objective of this scoping review is to identify obesity-related recommendations for peripartum care, evaluate grades of evidence for each recommendation, and identify practical tools (e.g., checklists, toolkits, care pathways, bundles) to support their implementation in clinical practice.

Data sources: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from inception to December 2020 for eligible studies addressing peripartum care in persons with obesity.

Study eligibility criteria: Inclusion criteria were published evidence-rated recommendations and practical tools for peripartum care of persons with obesity.

Study appraisal and synthesis methods: Pairs of independent reviewers extracted data (source, publication year, content and number of recommendations, level and grade of evidence, description of tool) and identified similarities and differences among the articles.

Results: Of 18,315 screened articles, 18 were included including 7 articles with evidence-rated recommendations and 11 practical tools (3 checklists, 3 guidelines, 1 care bundle, 1 flowchart, 1 care pathway, 1 care map, 1 protocol). Thirteen of 39 evidence-rated recommendations were based on expert opinion. Recommendations related to surgical antibiotic prophylaxis and subcutaneous tissue closure at cesarean delivery received the highest-grade of evidence. Some of the practical tools included a

1
2
3 checklist from the United States regarding anticoagulation after cesarean delivery
4
5 (evidence supported recommendation), a bundle for surgical site infections after
6
7 cesarean delivery in Australia (evidence did not support recommendation), and a
8
9 checklist with content for several aspects of peripartum care from Canada (evidence
10
11 supported seven of nine definitive recommendations).
12
13
14

15 Conclusion: The recommendations for peripartum care for persons with obesity are
16
17 based on limited evidence and few practical tools for implementation exist. Future work
18
19 should focus on developing practical tools based on high quality studies.
20
21
22

23 Strengths and limitations of this study:
24

- 25
26 • We may not have identified all articles with evidence-rated recommendations,
27
28 though our search of available published literature was thorough including a
29
30 search of appropriate web sites.
31
32
- 33 • Sites may have practical implementation tools that they use in the short- or long-
34
35 term, but they may not be published or available in a more public domain.
36
37
- 38 • Although topics such as contraception and postpartum weight management are
39
40 important in the postpartum care of persons with obesity, they were not
41
42 specifically addressed in this review, which pertained to peripartum care in the
43
44 immediate postpartum period.
45
46
- 47 • Obesity was typically defined according to a BMI ≥ 30.0 kg/m², but in many
48
49 instances the timing of the BMI was not provided (e.g., pre-pregnancy vs. at
50
51 delivery).
52
53
54
55
56
57
58
59
60

- We did not include recommendations that were intended for patient education only in this review.

Keywords: obesity, peripartum care, pregnancy, tools

For peer review only

INTRODUCTION

Obesity has reached epidemic proportions in the United States.[1] In 2015-2016, non-Hispanic Black (54.8%) and Hispanic (50.6%) women had the highest prevalence of obesity and 36.5% of reproductive age women (20-39 years) had obesity (BMI \geq 30.0 kg/m²), translating to a high percentage of persons with obesity during future pregnancies and race-ethnicity health disparities.[2] Of further concern, over 50% of persons with obesity exceed guidelines for weight gain during pregnancy, thus compounding their risks for adverse outcomes.[3-5] Adverse peripartum outcomes associated with obesity include cesarean delivery, infection, hemorrhage, thromboembolism (VTE), and anesthesia-related complications, such as failure of regional anesthesia and respiratory depression.[6] These adverse outcomes are amplified in persons with a BMI \geq 50 kg/m². [7] Furthermore, obesity is cited as a contributing factor in over 50% of maternal deaths.[8]

Adaptations to prenatal care for persons with obesity include early screening for diabetes and limiting weight gain to 11-20 pounds.[9] However, more evidence-based studies for peripartum care of persons with obesity, where the risk for adverse outcomes is a significant concern, are needed. For example, the National Institute for Health and Care Excellence (NICE) performed evidence-based reviews for the intrapartum management of obesity in 2019 and found no clinical evidence to suggest that the management of fetal monitoring or maternal positioning in labor should be altered.[10] Even fewer studies and evidence-based recommendations are available for those with a BMI \geq 50 kg/m², who are at even higher risk for adverse outcomes.

1
2
3 Strategies that have reduced adverse outcomes in obstetrics include the development
4 of checklists or toolkits after identifying patient, provider, and systems factors for
5 improvement in the care pathway.[11] Given the increasing incidence of obesity and
6 obesity-related complications, it is critical to identify opportunities to improve the safe
7 delivery of peripartum care.
8
9

10 11 12 13 14 15 **Objectives**

16
17 The objective of this scoping review is to identify obesity-related recommendations for
18 peripartum care, evaluate levels or grades of evidence for each recommendation, and
19 identify practical tools such as checklists, toolkits, or other comprehensive care
20 pathways to support their implementation in clinical practice. In this scoping review, we
21 were specifically interested in recommendations that pertained to actionable items such
22 as a treatment or decision option or a specialized consultation.
23
24
25
26
27
28
29
30
31
32

33 34 **METHODS**

35 **Eligibility criteria, information sources, search strategy**

36 The PRISMA extension for scoping reviews (PRISMA-ScR) checklist was used in
37 developing and reporting this scoping review.[12] The inclusion criteria were: (1)
38 published (in print or online) recommendations along with levels or grades of evidence
39 for the peripartum care of persons with obesity (BMI \geq 30.0 kg/m²), and if possible,
40 specifically for persons with a BMI \geq 50 kg/m²; or (2) published (in print or online)
41 description of a tool such as a checklist, toolkit, or comprehensive care pathway for the
42 peripartum care of obesity. We defined peripartum care to refer to care immediately
43 before, during and after delivery, approximately 24 hours before and after delivery. To
44 be included in the review, the identified recommendations needed to focus on
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 actionable items or management strategies, as opposed to being a listing of
4
5 comorbidities or risks that are associated with obesity in pregnancy. Actionable items
6
7 might include giving or withholding a particular medication or device. Recommendations
8
9 that exclusively related to “patient counseling” or imparting of knowledge to the patient
10
11 were not included as the interpretation of counseling can have different meanings
12
13 depending on the clinical setting (e.g., location of clinical practice, provider type). The
14
15 recommendations could have been abstracted from articles pertaining to obesity alone,
16
17 or other articles that specified recommendations pertaining to obesity (e.g., antibiotic
18
19 use in pregnancy with a specific adaptation for persons with obesity). Because
20
21 recommendations could be published from varying health care systems and there were
22
23 no restrictions placed on country of origin (e.g., national guidelines from United States
24
25 vs. United Kingdom), variances in evidence grading were identified and abstracted
26
27 according to the health care system’s grading method.
28
29
30
31
32

33 We searched PubMed MEDLINE, Embase (embase.com), Cochrane Central Register
34
35 of Controlled Trials (Wiley), CINAHL (EbscoHost), and clinicaltrials.gov from inception
36
37 through December 2020, with no date or language restrictions. The search for eligible
38
39 studies involved controlled vocabulary (MeSH headings and thesauri of relevant
40
41 databases) and the keywords of obesity, morbid obesity, super morbid obesity,
42
43 guidelines, recommendations, checklist, toolkit, maternal care pathway, peripartum
44
45 care, and pregnancy. The bibliographies of relevant reviews were hand-searched, as
46
47 well as key websites including Google Scholar. A full list of the sources and search
48
49 strategies is outlined in Appendix A.
50
51
52
53

54 **Patient and Public Involvement**

55
56
57
58
59
60

1
2
3 Patients were not directly involved in the design of this study.
4
5

6 **Study Selection**

7 The questions for this scoping review were: (1) What are the recommendations for
8 peripartum care of persons with obesity published by either individual authors, national
9 societies, or other government departments that provide levels or grades of evidence to
10 support the recommendation? (2) What are the published tools for practical
11 implementation of recommendations, either in the form of checklists, toolkits, or other
12 comprehensive care pathways?
13
14

15 The primary outcomes were the number of recommendations per article, topic of
16 recommendation, level or grade of evidence to support recommendations, and
17 similarities and differences between the recommendations across articles. For the
18 identified checklists, toolkits, or other comprehensive care pathways for the peripartum
19 management of obesity, their details were summarized and crosschecked with the
20 aforementioned recommendations.
21
22

23 **Data extraction**

24 Four reviewers independently screened all citations using the Covidence review
25 management software.[13] Initially, the reviewers were trained on a sample of 20
26 articles using the Covidence software to verify clarity and consistency regarding
27 inclusion and exclusion criteria. A separate, 5th reviewer resolved all conflicts. Once
28 agreement was obtained on articles meeting criteria for final inclusion, two reviewers
29 independently extracted the following data from each article using a form that was
30 tested and modified by the reviewers, as applicable: (1) source of recommendations
31 (e.g., individual authors, national societies, etc.), (2) year of publication, (3) content and
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

total number of recommendations, (4) level and grade of evidence for each of the recommendations, (4) system used to determine levels of evidence or classification of recommendations, (5) description of checklist, toolkit, comprehensive care pathway or other format used for implementation in the peripartum care of obesity. If articles were in abstract form only, we contacted the authors for updates on the status of the final publication.

Data synthesis

The data were summarized and abstracted into table format, noting key similarities and differences among the articles in terms of content and level and grade of evidence. For the identified checklists, toolkits, etc. similarities and differences among the content were highlighted. For this scoping review, we did not assess the effectiveness of the findings or evaluate bias. The scoping review protocol is published at <https://doi.org/10.18131/g3-gyms-ww23>.

Ethics approval statement

Ethics approval was not required since the study was a review of previously published articles.

RESULTS

Study selection

After removal of duplicates, 18,328 articles were screened, resulting in 203 articles for full-text review. Figure 1 shows the flow diagram for study selection. A total of 7 evidence-rated articles and 11 tools met inclusion criteria for this review. The majority (n=8) of the tools were selected from the results of Google Scholar searches.

Study characteristics

Table 1 displays the title, year of publication, source of recommendations, and references for evidence levels and grades for seven articles identified from the search of all databases. The publication years ranged from 2015-2020 representing three countries (US, UK, Canada) and one international guideline. Publication topics included thromboembolism, antibiotics prophylaxis, as well as the broad-spectrum of peripartum care. For these articles, the content was either exclusively focused on the management of obesity or the content was about a high-risk condition during pregnancy and addressed obesity among other issues. Table 2 displays the topic, content of the recommendation, and evidence levels and grades for each recommendation from the seven articles in Table 1. For the tools, Table 3 displays the title, year of publication, source of recommendations, and content topic for the peripartum management of obesity identified from searches of PubMed MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and CINAHL (n=3). Appendix B displays the same information identified from a search of key websites and Google Scholar for tools (n=8). We found a wide range of tools including checklists, bundles, flow charts, guidelines, protocols, care pathways, and care maps from practices in the United States, Canada, and the United Kingdom.

Table 1. Source of recommendations, year of publication, title, evidence grading system and levels and grades for 7 articles related to peripartum management of obesity

Author/Source	Date	Title	Evidence Grading System Examples of grade and level ranges
McAuliffe et al International Federation of Gynecology and Obstetrics	2020	Management of prepregnancy, pregnancy, and postpartum obesity[14]	GRADE[15] ^a Grade strong or weak Evidence low, moderate, high or best practice
Society for Maternal-Fetal Medicine (United States); 1/6 recommendations pertain to	2020	SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery[16]	GRADE[15] ^a Grade strong or weak Evidence low, moderate, high or best practice

1
2

3 obesity			
4 J van Schalkwyk, N Van Eyk 5 Society of Obstetricians and 6 Gynaecologists of Canada 7 (Canada); 1/7 8 recommendations pertain to 9 obesity	2017	Guideline No. 247-Antibiotic prophylaxis in obstetric procedures[17]	Canadian Task Force on Preventive Health Care [18] ^b Levels I-III Classifications A-I
10 Maxwell C, et al. 11 Society of Obstetricians and 12 Gynaecologists of Canada 13 (Canada)	2019, 2020 14 correction	Guideline No. 392-Pregnancy and maternal obesity Part 2: Team planning for delivery and postpartum care[19]	Canadian Task Force on Preventive Health Care [18] ^b Levels I-III Classifications A-E,I
15 Denison FC, et al. Royal 16 College of Obstetricians and 17 Gynaecologists (United 18 Kingdom)	2018	Care of women with obesity in pregnancy Green-top Guideline #72[20]	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines [21] ^c Grades A-D, and “checkmark” Levels 1++ to 4
19 Royal College of 20 Obstetricians and 21 Gynaecologists (United 22 Kingdom)	2015	Reducing the risk of venous thromboembolism during pregnancy and the puerperium Green-top Guideline No.37a[22]	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines [21] ^c Grades A-D, and “checkmark” Levels 1++ to 4
23 American College of 24 Obstetricians and 25 Gynecologists Practice 26 Bulletin (United States)	2015	Practice Bulletin #156 Obesity in pregnancy[9]	U.S. Preventive Services Task Force Grade A-C ^d Levels I-III

27
28 GRADE Grading of Recommendations Assessment, Development and Evaluation

29
30 SMFM Society for Maternal-Fetal Medicine

31
32 RCOG Royal College of Obstetricians and Gynaecologists

33
34 ^a GRADE: 1A. Strong recommendation, high quality evidence; 1B. Strong recommendation, moderate-
35 quality evidence; 1C. Strong recommendation, low quality evidence; 2A. Weak recommendation, high
36 quality evidence; 2B. Weak recommendation, moderate-quality evidence; 2C. Weak recommendation,
37 low quality evidence; Best practice

38
39 ^b Canadian Task Force on Preventive Health Care: Quality of evidence assessment: I: Evidence obtained
40 from at least one properly randomized controlled trial. II-1: Evidence from well-designed controlled trials
41 without randomization. II-2: Evidence from well- designed cohort (prospective or retrospective) or case-
42 control studies, preferably from more than one centre or research group. II-3: Evidence obtained from
43 comparisons between times or places with or without the intervention. Dramatic results in uncontrolled
44 experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this
45 category. III: Opinions of respected authorities, based on clinical experience, descriptive studies, or
46 reports of expert committees. Classification of recommendations: A. There is good evidence to
47 recommend the clinical preventive action. B. There is fair evidence to recommend the clinical preventive
48 action. C. The existing evidence is conflicting and does not allow to make a recommendation for or
49 against use of the clinical preventive action; however, other factors may influence decision-making. D.
50 There is fair evidence to recommend against the clinical preventive action. E. There is good evidence to
51 recommend against the clinical preventive action. L. There is insufficient evidence (in quantity or quality)
52 to make a recommendation; however, other factors may influence decision making.

53
54 ^c Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines: Classification of
55 evidence levels: 1++ High-quality meta-analyses, systematic reviews of randomised controlled trials or
56 randomised controlled trials with a very low risk of bias. 1+ Well-conducted meta-analyses, systematic
57

1
2
3 reviews of randomised controlled trials or randomised controlled trials with a low risk of bias. 1– Meta-
4 analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high
5 risk of bias. 2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–
6 control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the
7 relationship is causal. 2+ Well-conducted case–control or cohort studies with a low risk of confounding,
8 bias or chance and a moderate probability that the relationship is causal. 2– Case–control or cohort
9 studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not
10 causal. 3 Non-analytical studies, e.g. case reports, case series. 4 Expert opinion. Grades of
11 recommendation: A At least one meta-analysis, systematic review or RCT rated as 1++, and directly
12 applicable to the target population; or A systematic review of RCTs or a body of evidence consisting
13 principally of studies rated as 1+, directly applicable to the target population and demonstrating overall
14 consistency of results. B A body of evidence including studies rated as 2++ directly applicable to the
15 target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies
16 rated as 1++ or 1+. C A body of evidence including studies rated as 2+ directly applicable to the target
17 population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated
18 as 2++. D Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+. “Checkmark”
19 Recommended best practice based on the clinical experience of the guideline development group.

20
21 ^dU.S. Preventive Services Task Force: I Evidence obtained from at least one properly designed
22 randomized controlled trial. II-1 Evidence obtained from well-designed controlled trials without
23 randomization. II-2 Evidence obtained from well-designed cohort or case–control analytic studies,
24 preferably from more than one center or research group. II-3 Evidence obtained from multiple time series
25 with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as
26 this type of evidence. III Opinions of respected authorities, based on clinical experience, descriptive
27 studies, or reports of expert committees. Based on the highest level of evidence found in the data,
28 recommendations are provided and graded according to the following categories: Level A—
29 Recommendations are based on good and consistent scientific evidence. Level B—Recommendations
30 are based on limited or inconsistent scientific evidence. Level C—Recommendations are based primarily
31 on consensus and expert opinion.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Topics, recommendations, and level or grade of evidence among 7 articles related to peripartum management of obesity.

Topic	Recommendation	Level or grade of evidence
Route of delivery	The decision for a woman with maternal obesity to give birth by planned caesarean section should involve a multidisciplinary approach, taking into consideration the individual woman's comorbidities, antenatal complications and wishes.[20]	Level 2-, C
Labor induction	Induction of labor is recommended at 41+0 weeks of gestation for women with a BMI ≥ 35 owing to their increased risk of intrauterine death.[14]	Strong + + +
	Elective induction of labour at term in obese women may reduce the chance of caesarean birth without increasing the risk of adverse outcomes.[20]	Level 2+, B
	Where macrosomia is suspected, induction of labour may be considered. Parents should have a discussion about the options of induction of labour and expectant management.[20]	Level 1+, B
Fetal monitoring	Electronic fetal monitoring is recommended for women in active labor with a BMI ≥ 35. Intrauterine pressure catheters and fetal scalp electrodes may help.[14]	Conditional +
	(a) Electronic fetal monitoring can be considered for women in active labour with a body mass index > 35 kg/m ² . (b) Intrauterine pressure catheters may assist in assessment of labour contractions. (c) Fetal scalp electrodes may be helpful to ensure continuous fetal monitoring when indicated.[19]	III-B
Labor management	Allowing a longer first stage of labor before performing cesarean delivery for labor arrest should be considered in obese women.[9]	B, Level II-2,3
Blood pressure monitoring	Where available, an appropriately sized blood pressure cuff should be used for measurements. The cuff size used at the earliest time point should be documented in the medical records.[14]	Conditional ++
IV access	Establish venous access in early labor for women with a BMI ≥40 and consider a second cannula.[14]	Conditional +
	Women with a BMI 40 kg/m ² or greater should have venous access established early in labour and consideration should be given to the siting of a second cannula.[20]	Checkmark
Regional anesthesia	In the case of vaginal delivery for women with a BMI ≥ 40, early placement of an epidural catheter is advisable in the case of an emergency cesarean delivery.[14]	Conditional + +
Antibiotic prophylaxis for cesarean delivery	Women with a BMI ≥ 30 having a cesarean delivery are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery. Women with obesity may benefit from higher doses.[14]	Strong + + + +
	In patients with morbid obesity (BMI > 35), doubling the antibiotic dose may be considered.[17]	III-B
	Women with obesity may benefit from higher dosage of preoperative antibiotics for caesarean birth.[19]	I-A
	Women with class 1 obesity or greater having a caesarean section are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery.[20]	Level 1++, A
Incision type, skin closure for cesarean delivery	There is a paucity of high-quality evidence to support the use of one surgical approach over another. Surgical approaches should therefore follow NICE CG132 but clinicians may decide alternative approaches are merited depending on individual circumstances.[20]	Checkmark
Subcutaneous tissue closure	It is recommended to reapproximate the subcutaneous tissue layers at the time of caesarean birth to reduce wound complications.[19]	II-2A
	Women undergoing caesarean section who have more than 2 cm subcutaneous fat should have suturing of the subcutaneous tissue space in order to reduce the risk of wound infection and wound separation.[20]	Level 1++, A

36/bmjopen-2022-011430 on 18 September 2022. Downloaded from <http://bmjopen.bmj.com/> on 01 April 2023 by guest. Protected by copyright.

Topic	Recommendation	Level or grade of evidence
	Subcutaneous drains increase the risk of postpartum cesarean wound complications and should not be used routinely.[9]	Grade A, Level 1
	There is a lack of good-quality evidence to recommend the routine use of negative pressure dressing therapy, barrier retractors and insertion of subcutaneous drains to reduce the risk of wound infection in obese women requiring caesarean sections.[20]	Level 2- to 1+, B
Hemorrhage	Active management of the third stage should be recommended to reduce the risk of postpartum hemorrhage.[14]	Strong + + +
	Although active management of the third stage of labour is advised for all women, the increased risk of PPH in those with a BMI greater than 30 kg/m ² makes this even more important.[20]	Level 2++, A or Level 1++, B ^a
VTE prophylaxis	Postoperative pharmacologic thromboprophylaxis should be prescribed based on maternal weight.[14]	Conditional + +
	Mechanical thromboprophylaxis is recommended before and after cesarean delivery. Where available, women with a BMI ≥ 35 should be given graduated compression stockings, or other interventions such as sequential compression devices, after cesarean delivery until mobilization, which should be encouraged early.[14]	Conditional + +
	When pharmacologic thromboprophylaxis is needed in pregnant women with class III obesity, we suggest the use of intermediate doses of enoxaparin [for cesarean delivery].[16]	2C
	Postoperative thromboprophylaxis is recommended, at appropriate dosing for the given body mass index due to the greater risk of venous thromboembolism following caesarean birth with women with obesity.[19]	II-3 A
	All women with class 3 obesity (BMI greater than or equal to 40 kg/m ²) should be considered for prophylactic LMWH in doses appropriate for their weight for 10 days after delivery.[22]	D
	Women with two or more persisting risk factors listed in Table 1 should be considered for LMWH in prophylactic doses appropriate for their weight for 10 days after delivery. One risk factor = BMI ≥ 30kg/m ² . [22]	B
	Mechanical thromboprophylaxis is recommended before cesarean delivery, if possible, as well as after cesarean delivery.[9]	B, Level II-3
	Weight-based dosage for venous thromboembolism thromboprophylaxis may be more effective than BMI-stratified dosage strategies in class III obese women after cesarean delivery.[9]	B, Level II-3
Breastfeeding	Obesity is associated with low breastfeeding initiation and maintenance. Women with obesity in early pregnancy should receive specialist advice on the benefits of breastfeeding and appropriate antenatal and postnatal support for breastfeeding initiation and maintenance.[14]	Conditional + +
	Women with obesity should be offered lactation support in the postpartum period.[19]	III C
	Obesity is associated with low breastfeeding initiation and maintenance rates. Women with a booking BMI ≥ 30 kg/m ² or greater should receive appropriate specialist advice and support antenatally and postnatally regarding the benefits, initiation and maintenance of breastfeeding.[20]	Checkmark, Level 1+
Anesthesiology consult	Antenatal assessment with obstetric anaesthesia may assist in planning for safer birth for women with obesity.[19]	III-A
	The on-duty anaesthetist covering the labour ward should be informed of all women with class III obesity admitted to the labour ward for birth. This communication should be documented by the attending midwife in the notes.[20]	Checkmark
Systems	Where possible, healthcare facilities should have clearly defined pathways for the management of pregnant women with obesity. The adequacy of resources and equipment available should be considered when making decisions around care, especially for women with a BMI ≥ 40.[14]	Conditional +
	Obstetric team planning may be helpful for women with obesity to navigate the steps in antenatal, labour and delivery, and postnatal care.[19]	III-3 A ^b

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Topic	Recommendation	Level or grade of evidence
	Consultation with anesthesia service should be considered for obese pregnant women with OSA because they are at an increased risk of hypoxemia, hypercapnia, and sudden death.[9]	C

^a The recommendation is reports as “Level 2++, A” on page 26 of the document and also reported as “Level 1++, B” on pages 8 and 30 of the document.

^b The recommendation is reported as “III-3 A”, though this level and grade of evidence is not defined in the Society of Obstetricians and Gynaecologists of Canada document.

BMI body mass index

NICE CG National Institute for Health and Care Excellence Clinical Guidelines

VTE venous thromboembolism

PPH postpartum hemorrhage

IV intravenous

LMWH low molecular weight heparin

OSA obstructive sleep apnea

36/bmjopen-2022-061430 on 1 September 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.




Table 3: Title, year of publication, source of recommendations, content topic, and evidence to support recommendation among 3 tools related to the peripartum management of obesity

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Title	Year	Source or Site	Tool type	Content	Evidence to support content when a definitive recommendation was made in the tool
Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery[23]	2020	Society for Maternal-Fetal Medicine	Checklist	VTE prophylaxis (after cesarean delivery) For women with body mass index (BMI) 40 kg/m ² or greater (class 3 obesity) who have thrombophilia or history of deep venous thrombosis or pulmonary embolism, intermediate-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg SC every 12 hours); continue for 6 weeks postoperatively	SMFM[16] Level 2C
Reducing surgical site infections post-cesarean section in an Australian hospital, using a bundled care approach[24]	2020	NSW Local Health District, Australia	Bundle	Subcutaneous tissue closure Negative pressure wound therapy BMI>35 (PICO) BMI > 40 (Prevena) applied in operating suite at the time of incision closure and left in-situ for 7 days	RCOG[20] Level 2- to 1+, B does NOT support recommendation
Team Planning in Obstetrical Care for Women with Obesity[25]	2019	Mount Sinai Hospital in Toronto, Ontario Canada	Checklist	General admission for delivery PICC line recommended (checkbox) Intrapartum Type of delivery (spontaneous or induced labor or Cesarean delivery) (checkbox) Appropriate size [blood pressure] cuff Appropriate size gown, long monitoring belts Notify OB, Anesthesia, Respiratory therapist, Neonatology May need cross and type IUPC use (checkbox) Encourage ambulation Cesarean delivery	FIGO[14] Conditional ++ for BP cuff size RCOG[20] “Checkmark” for notify anesthesia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Incision location
 Method of [incision] closure
 Use of negative pressure wound system (checkbox).
 Plan for prolonged length of stay if OSA/CPAP (checkbox)
 Additional medication for gastric emptying/GERD and possible additional antibiotics
 Equipment (OR table with side bars and pads, OR tray, hover mat, epidural/spinal needle and portable ultrasound, Troop pillow, need for difficult airway try, Mobius retractor and Sturgeon, Traxi Panniculus retractor, negative pressure wound system)
 Need for increased length of stay due to anesthesia (checkbox) (e.g., CPAP for sleep apnea).
Postpartum
 Bariatric bed required for a weight > 500 lbs. (check box)
 Delay in suture or staple removal with the postoperative day entered for removal as an outpatient.
 Prophylactic anticoagulation, early ambulation encouraged
 Pain management plan with dosage changes
 Breastfeeding, lactation consultant
 Dietician follow-up

SOGC[17, 19] Level 1-A and Level III-B for additional antibiotics
 FIGO[14] Conditional 1+ for resources an equipment
 FIGO[14] Conditional 1+ for resources an equipment
 None
 SMFM[16] Level 2C, FIGO Conditional ++[14], SOGC[19] II-3, RCOG[20] Grade B or D, ACOG[9] Grade B Level 2-3
 None
 FIGO[14] Conditional ++, RCOG[20] "checkmark", Level 1+

SMFM Society for Maternal-Fetal Medicine
 BMI body mass index
 SC subcutaneous

36/bmjopen-2022-061430 on 19 September 2022. Downloaded from <http://bmjopen.bmj.com/> on 19 September 2022 by guest. Protected by copyright.

1
2
3 NSW North South Wales

4
5 RCOG Royal College of Obstetricians and Gynecologists

6
7 PICC peripherally inserted central catheter

8
9 BP blood pressure

10
11 OB obstetrics

12
13 IUPC intrauterine pressure catheter

14
15 OSA obstructive sleep apnea

16
17 CPAP continuous positive airway pressure

18
19 FIGO International Federation of Gynecology and Obstetrics

20
21 SOCG Society of Obstetricians and Gynaecologists of Canada

22
23 OR operating room

24
25 VTE venous thromboembolism

26
27 ACOG American College of Obstetricians and Gynecologists

Synthesis of Results

The evidence-rated recommendations covered topics such as labor induction (e.g., indication and timing), intravenous access, fetal monitoring (e.g., scalp electrodes, intrauterine pressure catheters), management of the 1st and 3rd stages of labor, breastfeeding, and system-related preparedness. Several recommendations were specific to cesarean delivery (e.g., incision type, antibiotic prophylaxis and dose, subcutaneous tissue closure, negative pressure dressings, and VTE prophylaxis) and anesthesia (e.g., consultation, early placement of an epidural catheter). In several instances, recommendations for persons with obesity did not differ from recommendations for persons without obesity (e.g., antibiotic prophylaxis for cesarean delivery).[20] Three articles had one recommendation [16, 17, 22] and the highest number of recommendations was 11 in a single article.[14] The FIGO (International Federation of Gynecology and Obstetrics) Pregnancy and Non-Communicable Disease Committee published guidelines for the management of pre-pregnancy, pregnancy, and postpartum obesity. Their recommendations for peripartum management (n=11) were included in this analysis, but it should be noted that the recommendations were not unique to the article, but instead they were abstracted from previously published international articles.[14]

The recommendations that were of the highest grade (Strong, Level 1, or Grade A) were antibiotic prophylaxis for cesarean delivery,[14, 20] higher dosage of preoperative antibiotics for cesarean delivery,[17, 19] and subcutaneous tissue closure.[9, 20] We noted that 13 recommendations were based on expert opinion or the lowest level of evidence. We noted that topics such as antibiotic prophylaxis (n=4

1
2
3 recommendations),[14, 17, 19] subcutaneous skin closure (n=4 recommendations),[9,
4
5 19, 20] and VTE prophylaxis (n=8 recommendations)[9, 14, 16, 19] were most
6
7 commonly addressed. There were two instances where a particular intervention was not
8
9 recommended (e.g., subcutaneous drains, negative pressure dressing therapy).[9, 20]
10
11 We did not find any recommendations that directly opposed one other, but there were
12
13 differences in the specifics of the recommendations. For example, the American College
14
15 of Obstetricians and Gynecologists (ACOG) recommends an anesthesiology consult for
16
17 persons with both obesity and obstructive sleep apnea whereas RCOG recommends
18
19 that the anesthetist “be informed of all women with class III obesity”.[9, 20] In one
20
21 guideline from the Society of Obstetricians and Gynaecologists of Canada (SOGC), the
22
23 recommendation is for a “higher” dose [19] and another recommendation from the
24
25 SOGC is for a “double dose” [17] of antibiotic prophylaxis. Regarding specific
26
27 recommendations for persons with different classes of obesity, we only found
28
29 recommendations for weight-based VTE prophylaxis dosing [9, 16, 22] and
30
31 anesthesiology consultations.[20]
32
33
34
35
36
37

38 Regarding the practical tools for implementation (Table 3), the style varied. In a
39
40 checklist and bundle, there were specific recommendations including “40 mg of
41
42 enoxaparin subcutaneously twice daily for VTE prophylaxis after cesarean delivery” [23]
43
44 and “negative pressure wound therapy...applied in operating suite at the time of incision
45
46 closure and left-in-situ for 7 days”, respectively.[24] Another checklist had several
47
48 recommendations for intrapartum and postpartum care with check boxes (e.g.,
49
50 intrauterine pressure catheter use, incision type, negative pressure dressing therapy),
51
52 ultimately leaving the decision to perform the intervention or not up to the individual
53
54
55
56
57
58
59
60

1
2
3 provider.[25] Common terms found in the tools from Google Scholar searches included
4
5 “consider” a certain treatment option or “anticipate” a particular complication (Appendix
6
7 B). We noted differences in these tools for continuous fetal monitoring, where two tools
8
9 recommend continuous fetal monitoring,[26, 27] but one did not.[28] In addition, two
10
11 tools [24, 29] recommended negative pressure dressing therapy for certain
12
13 circumstances (e.g., BMI > 35 kg/m² or > 40 kg/m²) whereas another tool stated “avoid
14
15 the use of wound vacs.”[26]
16
17

18
19 We then evaluated the similarities and differences between the evidence-rated
20
21 recommendations in Table 2 and any of the published tools in Table 3. The evidence to
22
23 support or not support the content in the tools from Table 2 was provided in the last
24
25 column of Table 3. Some of the differences noted are as follows. The one
26
27 recommendation in the checklist from the Society for Maternal-Fetal Medicine was
28
29 supported from its own clinical series article.[16, 23] The recommendation from the
30
31 bundle for prophylactic negative pressure wound therapy to reduce surgical site
32
33 infection at a hospital in New South Wales, Australia was not supported by any
34
35 recommendations in Table 2.[24] We observed that evidence-rated recommendations
36
37 supported the majority of the content in the checklist from Abdelmalek et al. These
38
39 included to notify anesthesiology providers, have resources available to accommodate
40
41 increased weight (e.g., operating room equipment, blood pressure cuffs), give
42
43 prophylactic anticoagulation (though dose adjustments not specified), and have a
44
45 lactation consultation.[25] However, content such as delay in staple removal or
46
47 adjustments in postpartum pain management were not found in other evidence-rated
48
49 recommendations in Table 2.
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Principal Findings

In our scoping review of the peripartum management of obesity, we found seven articles with evidence-rated recommendations. The articles included national guidelines from the FIGO (n=11 recommendations), United States (n=6 recommendations), United Kingdom (n=13 recommendations), and Canada (n=9 recommendations). The majority of the levels of evidence were second or third tier (Level 2 from GRADE, Level II or III from Canadian Task Force on Preventive Health Care, or Grade B or C from US Preventive Services Task Force). The recommendation that was of the highest grade (Strong, Level 1 or Grade A) was antibiotic prophylaxis for cesarean delivery,[14, 20] yet these recommendations apply to persons of all weights. A higher dosage of preoperative antibiotics for cesarean delivery also had the highest grade in one article[19] as well as subcutaneous tissue closure.[9, 20] We noted that 13 recommendations were based on expert opinion, or the lowest level of evidence. We noted that the majority of these recommendations would be considered “low-risk” interventions such as lactation and anesthesia consults and developing a system or clinical care pathway for persons with obesity. Other expert opinion recommendations might be considered in the labor management for all persons depending on the clinical situation (e.g., intravenous access, fetal heart rate monitoring, IUPC use).

Although we did not find directly opposing recommendations, there were subtle differences in some of the recommendations including criteria for anesthesia consults and antibiotic dosing. There is considerable debate over appropriate prophylactic dosing of antibiotics for cesarean delivery in persons with obesity given that pharmacokinetic

1
2
3 studies suggest improved or similar tissue concentrations with adjusted dosing,[30-33]
4
5 whereas a study comparing clinical outcomes such as surgical site infections did not
6
7 demonstrate significant differences when comparing standard vs. higher doses of
8
9 antibiotics.[34] The variations in recommendations may reflect the uncertainty of
10
11 whether to reach a physiological target vs. a clinical outcome.
12
13

14
15 We found that the recommendation for prophylactic negative pressure therapy in one
16
17 tool contradicted the Royal College of Obstetricians and Gynaecologists'
18
19 recommendation regarding this practice ("There is a lack of good-quality evidence to
20
21 recommend the routine use of negative pressure dressing therapy...").[20] We
22
23 acknowledge the content in the tools may be unique to a site depending on available
24
25 resources at the time of peripartum care as well as historical practice patterns, cost,
26
27 ease of use, and risk/benefit ratio to maternal and fetal health. In the tools we reviewed,
28
29 language such as "consider" or "anticipate" suggests that a concrete recommendation is
30
31 not available and care needs to be individualized.
32
33
34
35

36 **Strengths and limitations in relation to other studies**

37
38 Other authors have published summaries of clinical guidelines, similar to the ones we
39
40 identified. For example, a systematic review of guidelines available worldwide for the
41
42 management of obesity in pregnancy found 32 clinical practice guidelines covering the
43
44 domains of preconception care, care during pregnancy, diet and exercise during
45
46 pregnancy, care immediately before, during and after delivery, and postpartum care.[35]
47
48 For delivery and postpartum care, those authors identified the following
49
50 recommendations: (1) obesity alone not an indication for induction of labor, (2) early
51
52 establishment of venous access during labor for women with a BMI > 40 kg/m², (3)
53
54
55
56
57
58
59
60

1
2
3 allowing for a longer 1st stage of labor before performing a cesarean delivery for labor
4
5 arrest, and (4) active management of the 3rd stage of labor. Recommendations
6
7 pertaining to cesarean delivery included: (1) obesity alone not an indication for elective
8
9 cesarean delivery, (2) need for adequate staffing and equipment for maternal weight >
10
11 120 kg, (3) suturing subcutaneous tissue if > 2 cm of depth, (4) use of mechanical
12
13 thromboprophylaxis before and after cesarean delivery, and (5) weight-based dosing of
14
15 medication used to prevent VTE. Lastly, they also identified recommendations for
16
17 breastfeeding support and lactation consultants. These recommendations were similar
18
19 to the ones we identified from national guidelines in our scoping review.[9, 19, 20]
20
21
22
23
24 Several of the evidence-rated recommendations in Table 2 supported the content in the
25
26 11 tools we identified. However, we also found content not supported by evidence-rated
27
28 recommendations such as a peripherally inserted catheter for difficult intravenous
29
30 access and delayed staple removal. We identified a randomized controlled non-
31
32 inferiority trial of early (post-operative day 3) or delayed (between post-operative days 7
33
34 and 10) staple removal for transverse skin incisions in persons with a BMI \geq 30
35
36 kg/m².^[36] Although the study was stopped prior to reaching the targeted sample size,
37
38 the occurrence of superficial wound dehiscence was 15.2% in the early and 11.5% in
39
40 the delayed group (RR 1.3, 95% CI 0.7-2.4) and there were no other differences in the
41
42 secondary outcomes of seroma, hematoma, surgical site infection, or pain scores
43
44 among the two groups. Since the available evidence regarding timing of staple removal
45
46 is limited, other clinical and non-clinical characteristics such as provider and patient
47
48 preference likely contribute to decisions about staple removal timing.
49
50
51
52
53

54 **Strengths and limitations of this study**

55
56
57
58
59
60

1
2
3 We acknowledge several limitations to our study. We may not have identified all articles
4 with evidence-rated recommendations, though our search of available published
5 literature was thorough including a search of appropriate web sites. Sites may have
6 practical implementation tools that they use in the short- or long-term, but they may not
7 be published or available in a more public domain. We identified clinical guidelines from
8 other countries including Ireland and Australia,[37, 38] but they were not included in this
9 review because they were not accompanied by evidence-rated recommendations.
10
11 Although topics such as contraception and postpartum weight management are
12 important in the postpartum care of persons with obesity, they were not specifically
13 addressed in this review, which pertained to peripartum care in the immediate
14 postpartum period. Obesity was typically defined according to a BMI ≥ 30.0 kg/m², but in
15 many instances the timing of the BMI was not provided (e.g., pre-pregnancy vs. at
16 delivery). Some recommendations were specific to a particular BMI cut-off, but others
17 pertained to obesity, in general, without specifying a BMI. Lastly, we did not include
18 recommendations that were intended for patient education only in this review.

38 **Meaning of the study**

39
40
41 Based on this scoping review, we propose the following key content for a peripartum
42 checklist or toolkit in Table 4. This content is based on evidence ratings and ease of
43 implementation. In summary, persons with obesity are at high risk for morbidity and
44 mortality, with an abundance of risk occurring during the peripartum period. Few
45 guidelines exist for the care of these persons and the evidence to support care is
46 limited. Thus, there is a need for high quality studies encompassing peripartum
47 interventions.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4: Proposed key content for a peripartum checklist or toolkit for persons with obesity

Content	Examples
Provider discussion on labor induction, delivery route, and labor management	Allow for longer labor Difficulties in fetal heart rate monitoring
Expert consultations	Anesthesiologists Lactation consultants
Prophylaxis for cesarean delivery	Mechanical devices for VTE prophylaxis Higher dose of antibiotic before delivery depending on BMI Higher dose of anticoagulant after delivery depending on BMI
Wound management	Close subcutaneous tissue without drains or wound therapy

Conclusion

The recommendations for peripartum care for persons with obesity are based on limited evidence and few practical tools for implementation exist. Future work should focus on developing practical tools based on high quality studies.

Contributorship statement

MK designed the study protocol. LCO completed the database search of potential articles. MK, IC, JMP, AP, and PT reviewed abstracts, decided on inclusion and exclusion criteria, and reviewed the full-text of included articles. All authors contributed to the synthesis of results. All authors acknowledged approval of the final version for publication.

Competing interests

The authors have no competing interests to report.

Funding

There are no financial support resources to report.

Data sharing

The protocol is available for review at <https://doi.org/10.18131/g3-gyms-ww23>. A full list of the sources and search strategies is outlined in Appendix A.

REFERENCES

1. Ogden, C.L., et al., Prevalence of childhood and adult obesity in the United States, 2011-2012. *JAMA*, 2014. **311**(8): p. 806-14.
2. Hales, C.M., et al., Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief*, 2017(288): p. 1-8.
3. Moore Simas, T.A., et al., Efforts needed to provide Institute of Medicine-recommended guidelines for gestational weight gain. *Obstet Gynecol*, 2010. **115**(4): p. 777-83.
4. Bodnar, L.M., et al., Severe obesity, gestational weight gain, and adverse birth outcomes. *Am J Clin Nutr*, 2010. **91**(6): p. 1642-8.
5. Deputy, N.P., A.J. Sharma, and S.Y. Kim, Gestational Weight Gain - United States, 2012 and 2013. *MMWR Morb Mortal Wkly Rep*, 2015. **64**(43): p. 1215-20.
6. Gunatilake, R.P. and J.H. Perlow, Obesity and pregnancy: clinical management of the obese gravida. *Am J Obstet Gynecol*, 2011. **204**: p. 106-19.
7. Marshall, N.E., et al., Maternal superobesity and perinatal outcomes. *Am J Obstet Gynecol*, 2012. **206**(5): p. 417 e1-6.
8. Knight M, N.M., Tuffnell D, Shakespeare J, Kenyon S, Kurinczuk JJ (Eds.), *Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-2015*. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2017. 2017.
9. ACOG Practice Bulletin No 156: Obesity in Pregnancy. *Obstet Gynecol*, 2015. **126**(6): p. e112-e126.
10. National Institute for Health and Care Excellence Clinical Guidelines. *Intrapartum care for women with existing medical conditions or obstetric complications and their babies*. London, 2019.
11. BERNSTEIN PS, COMBS CA, Shields LE, Clark SL, Eppes CS. The development and implementation of checklists in obstetrics. *Am J Obstet Gynecol* 2017;217:B2-B6.
12. Tricco, A.C., et al., PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*, 2018. **169**(7): p. 467-473.
13. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
14. McAuliffe, F.M., et al., Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: A FIGO (International Federation of Gynecology and Obstetrics) guideline. *Int J Gynaecol Obstet*, 2020. **151 Suppl 1**: p. 16-36.
15. Guyatt, G.H., et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. **336**(7650): p. 924-6.
16. PACHECO LD, SAADE G, METZ TD. Society for Maternal-Fetal Medicine Consult Series #51: Thromboembolism prophylaxis for cesarean delivery. *Am J Obstet Gynecol* 2020;223:B11-B17.
17. van Schalkwyk, J. and N. Van Eyk, No. 247-Antibiotic Prophylaxis in Obstetric Procedures. *J Obstet Gynaecol Can*, 2017. **39**(9): p. e293-e299.

18. CANADIAN TASK FORCE ON PREVENTIVE HEALTH C. New grades for recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ* 2003;169:207-8.
19. Maxwell, C., et al., Guideline No. 392-Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care. *J Obstet Gynaecol Can*, 2019. **41**(11): p. 1660-1675.
20. Denison, F.C., et al., Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72. *BJOG*, 2019. **126**(3): p. e62-e106.
21. Royal College of Obstetricians and Gynaecologists. Developing a Green-top Guideline: Guidance for developers. London: RCOG, 2020.
22. RCOG. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. April 2015.
23. COMBS CA. Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery. *Am J Obstet Gynecol* 2020;223:B22-B23.
24. Bolte, M., et al., Reducing surgical site infections post-caesarean section in an Australian hospital, using a bundled care approach. *Infect Dis Health*, 2020. **25**(3): p. 158-167.
25. Abdelmalek, M.Z., S. Guest, and C. Maxwell, Team Planning in Obstetrical Care for Women With Obesity. *J Obstet Gynaecol Can*, 2019. **41**(3): p. 338-343.
26. University of New Mexico School of Medicine. Standard operating procedure-guideline class 3 obesity and pregnancy. 2020. Available from: <http://unmobgyn.pbworks.com/w/file/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf> [cited 2021 4.1.2021].
27. Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg>.
28. Obesity in pregnancy guidelines. 2020 [cited 2021 4.1.2021]; Available from: <https://www.northdevonhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf>
29. Antenatal management of obesity. 2018 [cited 2021 4.1.2021]; Available from: [www.spectrumhealth.org>mfm>protocol-obesity](http://www.spectrumhealth.org/mfm/protocol-obesity).
30. Kram, J.J.F., et al., Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? *Eur J Obstet Gynecol Reprod Biol*, 2017. **210**: p. 334-341.
31. Young, O.M., et al., Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. *Am J Obstet Gynecol*, 2015. **213**(4): p. 541 e1-7.
32. Maggio, L., et al., Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. *Obstet Gynecol*, 2015. **125**(5): p. 1205-1210.
33. Grupper, M., et al., Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. *J Clin Pharmacol*, 2017. **57**(6): p. 712-719.


- 1
- 2
- 3
- 4 34. Ahmadzia, H.K., et al., Obstetric Surgical Site Infections: 2 Grams Compared
- 5 With 3 Grams of Cefazolin in Morbidly Obese Women. *Obstet Gynecol*, 2015.
- 6 **126**(4): p. 708-715.
- 7 35. Simon, A., et al., Guidelines for the management of pregnant women with
- 8 obesity: A systematic review. *Obes Rev*, 2020. **21**(3): p. e12972.
- 9 36. Nuthalapaty, F.S., et al., A randomized controlled trial of early versus delayed
- 10 skin staple removal following caesarean section in the obese patient. *J Obstet*
- 11 *Gynaecol Can*, 2013. **35**(5): p. 426-433.
- 12 37. Institute of Obstetricians and Gynaecologists Royal College of Physicians of
- 13 Ireland. Obesity and Pregnancy Clinical Practice Guideline. Guideline No.2 June
- 14 2011, revised June 2013.
- 15 38. The Australian and New Zealand College of Obstetricians and Gynaecologists.
- 16 C-Obs 49 Management of Obesity in Pregnancy. 2013.
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1: PRISMA flow diagram for study selection.

For peer review only



PRISMA Flow Diagram



Examples for exclusion:
^a Only study protocol or abstract available
^b Intervention may have occurred during prenatal care or postpartum, but not during delivery

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Appendix A Search Strategy

PubMed MEDLINE

Guidelines search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient[tiab] OR Parturients[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab]) AND (Toolkit[tiab] OR toolkits[tiab] OR Guideline[tiab] OR guidelines[tiab] OR Recommend*[tiab] OR Checklist[tiab] OR checklists[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR "Best practice"[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR "Network Meta-Analysis"[Mesh] OR systematic[ti] OR scoping[ti] OR meta-analy*[ti])

Interventions search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient*[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab])

AND (Toolkit*[tiab] OR Guideline*[tiab] OR Recommend*[tiab] OR Checklist*[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR Best practice*[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Early Medical Intervention"[Mesh] OR "Patient Education as Topic"[Mesh] OR "Health Education"[Mesh] OR intervention*[tiab] OR therapy[subheading] OR therapy[tiab] OR treatment[tiab])

AND

("Case-Control Studies"[Mesh:noexp] OR "retrospective studies"[mesh:noexp] OR "Control Groups"[Mesh:noexp] OR (case[TIAB] AND control[TIAB]) OR (cases[TIAB] AND controls[TIAB]) OR (cases[TIAB] AND controlled[TIAB]) OR (case[TIAB] AND comparison*[TIAB]) OR (cases[TIAB] AND comparison*[TIAB]) OR "control

group"[TIAB] OR "control groups"[TIAB] OR cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] OR randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh]))

Filters used for the interventions search:

http://libguides.sph.uth.tmc.edu/search_filters/pubmed_filters

<https://work.cochrane.org/pubmed>

Embase (embase.com)

Guidelines search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'evidence based practice'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR Toolkit*:ti,ab OR Guideline*:ti,ab OR Recommend*:ti,ab OR Checklist*:ti,ab OR consensus:ti,ab OR Evidence-based:ti,ab OR 'Best practice*':ti,ab OR "Clinical management":ti,ab OR "Anesthetic management":ti,ab OR anesthesia:ti,ab OR anaesthesia:ti,ab OR Standards:ti,ab OR systematic:ti OR scoping:ti OR meta-analy*:ti

Interventions search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR toolkit*:ti,ab OR guideline*:ti,ab OR recommend*:ti,ab OR checklist*:ti,ab OR consensus:ti,ab OR 'evidence based':ti,ab OR 'best practice':ti,ab OR 'clinical management':ti,ab OR 'anesthetic management':ti,ab OR standards:ti,ab OR 'intervention study'/exp OR 'patient education'/exp OR 'health education'/exp OR 'therapy'/exp OR intervention*:ti,ab OR therapy:ti,ab OR treatment:ti,ab

AND

'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind procedure':de OR (random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* NEAR/1 blind* OR assign* OR allocat* OR volunteer*):de,ab,ti OR 'clinical article'/exp OR 'controlled study'/exp OR 'major clinical study'/exp OR 'prospective study'/exp OR 'cohort analysis'/exp OR 'cohort':ti,ab OR 'compared':ti,ab OR 'groups':ti,ab OR 'case control':ti,ab OR 'multivariate':ti,ab

Filters:

<https://guides.library.harvard.edu/c.php?g=309982&p=2079546>

<https://work.cochrane.org/embase>

CENTRAL: Cochrane Register of Controlled Trials

Guidelines and intervention search

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 (Obesity OR Obese OR Superobesity):ti,ab,kw

- 1
2
3 #3 #1 OR #2
4
5 #4 MeSH descriptor: [Pregnancy] explode all trees
6
7 #5 MeSH descriptor: [Pregnancy Complications] explode all trees
8
9 #6 MeSH descriptor: [Pregnant Women] explode all trees
10
11 #7 MeSH descriptor: [Delivery, Obstetric] explode all trees
12
13 #8 MeSH descriptor: [Peripartum Period] explode all trees
14
15 #9 MeSH descriptor: [Perinatal Care] explode all trees
16
17 #10 Pregnancy:ti,kw,ab OR Pregnancies:ti,kw,ab OR Pregnant:ti,kw,ab OR
18 Parturition:ti,kw,ab OR Parturient*:ti,kw,ab OR Peripartum:ti,kw,ab OR Perinatal:ti,kw,ab
19 OR Prenatal:ti,kw,ab OR Antenatal:ti,kw,ab OR Antepartum:ti,kw,ab OR
20 Intrapartum:ti,kw,ab OR Postpartum:ti,kw,ab OR Cesarean:ti,kw,ab
21
22 #11 {OR #4-#10}
23
24 #12 Toolkit*:ti,kw,ab OR Guideline*:ti,kw,ab OR Recommend*:ti,kw,ab OR
25 Checklist*:ti,kw,ab OR consensus:ti,kw,ab OR Evidence-based:ti,kw,ab OR Best
26 practice*:ti,kw,ab OR “Clinical management”:ti,kw,ab OR “Anesthetic
27 management”:ti,kw,ab OR anesthesia:ti,kw,ab OR anaesthesia:ti,kw,ab OR
28 Standards:ti,kw,ab
29
30
31 #13 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
32
33 #14 systematic:ti OR scoping:ti OR meta-analy*:ti
34
35 #15 #12 OR #13 OR #14
36
37 #16 #3 AND #11 AND #15
38
39 #17 MeSH descriptor: [Early Medical Intervention] explode all trees
40
41 #18 MeSH descriptor: [Patient Education as Topic] explode all trees
42
43 #19 MeSH descriptor: [Health Education] explode all trees
44
45 #20 MeSH descriptor: [Therapeutics] explode all trees
46
47 #21 intervention*:ti,kw,ab OR therapy:ti,kw,ab OR treatment:ti,kw,ab
48
49 #22 {OR #17-#21}
50
51 #23 #3 AND #11 AND #22
52
53 #24 #16 OR #23
54
55
-

CINAHL (EbscoHost)**Guidelines search**

((MH "Obesity") OR (MH "Obesity, Morbid")) OR TI (Obesity OR Obese OR Superobesity) OR AB (Obesity OR Obese OR Superobesity)

AND

((MH "Pregnancy+") OR (MH "Pregnancy, Multiple+") OR (MH "Pregnancy Trimesters+") OR (MH "Pregnancy, Unplanned") OR (MH "Pregnancy, Unwanted") OR (MH "Expectant Mothers") OR (MH "Pregnancy Complications+") OR (MH "Obstetric Care+") OR (MH "Postnatal Care+") OR (MH "Postnatal Period+")) OR TI (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean) OR AB (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean)

AND

((MH "Practice Guidelines") OR (MH "Meta Analysis") OR (MH "Meta Synthesis")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR TI (systematic OR scoping OR meta-analy*)

Interventions search

((MH "Early Intervention") OR (MH "Patient Education+") OR (MH "Health Education+") OR (MH "Pregnancy Outcomes") OR (MH "Treatment Outcomes+")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment)

AND

(MH "Prospective Studies") OR TI (cohort OR longitudinal OR prospective OR retrospective) OR AB (cohort OR longitudinal OR prospective OR retrospective) OR ((MH "Random Assignment") or (MH "Random Sample+") or (MH "Crossover Design") or (MH "Clinical Trials+") or (MH "Comparative Studies") or (MH "Control (Research)+") or (MH "Control Group") or (MH "Factorial Design") or (MH "Quasi-Experimental Studies+") or (MH "Placebos") or (MH "Meta Analysis") or (MH "Sample Size") or (MH "Research, Nursing") or (MH "Research Question") or (MH "Research Methodology+") or (MH "Evaluation Research+") or (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") or (MH "Nursing Practice, Research-Based") or (MH "Solomon Four-Group Design") or (MH "One-Shot Case Study") or (MH "Pretest-Posttest Design+") or (MH "Static Group Comparison") or (MH "Study Design") or (MH "Clinical Research+")) or (clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or meta?analy* or systematic review* or blind* or mask* or trial*))

Clinicaltrials.gov

Keyword searches included pregnancy and obesity.

Google searches

Recognizing that guidelines, toolkits, and checklists are often not published in the journal literature, we supplemented the guidelines search strategy with Google searches. To ensure more precision we limited the results to .org and .gov domains.

Searches were run in Google for "obesity pregnancy guideline" with the following limits:

1. Words in page title only
2. Words in URL only
3. .org domain
4. .gov domain
5. .gov.uk domain
6. .org.uk domain
7. .gov.au domain
8. .org.au domain

On the assumption that the Google search algorithm pushes the most relevant results to the top, one reviewer (MK) screened the first four pages of results for each search, looking for guidelines and checklists not already included in our previous search results. For the identified sites, the other authors (PT, AP, IC, JP) also voted to include or exclude the sites. The most recent search was conducted in April 2021.

36/bmjopen-2022-061430 on 15 September 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Title	Year	Source or Site	Tool type	Content
Obesity in Pregnancy ^{1 a}	8.2021	Department of Health in Queensland, AU Guideline: Obesity and pregnancy (including post bariatric surgery) (health.qld.gov.au)	Flow Chart	Intrapartum If BMI > 40 kg/m ² Early assessment of IV access Recommend continuous fetal monitoring If prophylactic antibiotics, consider higher dosage Active third stage management Surveillance for shoulder dystocia/PPH Postpartum Surveillance for airway compromise Early mobilisation Assess risk of VTE and consider thromboprophylaxis Additional support for breastfeeding
Class 3 Obesity and Pregnancy ²	7.2020	University of New Mexico Department of Obstetrics and Gynecology http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf	Standard operating procedure-guideline	Intrapartum No clear evidence for routine IOL solely for class 3 obesity Higher morbidity with TOLAC compared to repeat CD in this specific population Consider repeat CD in this population Alert team of increased risk of shoulder dystocia and PPH Anesthesia evaluation before admission, or early in admission Pneumatic compression stockings during labor Continuous fetal and uterine monitoring in labor Avoid use of wound vacs or drains Postpartum Low-molecular weight heparin for thromboprophylaxis for 5-6 days postpartum Weight based prophylaxis is better option Breast feeding encouraged due to higher risks of difficulties Lactation counseling Consider lactation consulting Incentive spirometry Early ambulation Avoid early hospital discharge
Obesity in Pregnancy ³	4.2018	Alaska Native Medical Center https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf	Guideline	Intrapartum Use appropriate sized blood pressure cuff Anticipate higher dose of oxytocin for induction or augmentation of labor Consider placement of prophylactic epidural catheter If BMI > 40 kg/m² Consider early IUPC and FSE

				<p>If BMI > 50 kg/m² Anesthesia consult on admission Consider additional use of IV famotidine and/or metoclopramide Anticipate higher rate of failed regional anesthesia Anticipate difficult airway (have videolaryngoscope available, have laryngeal mask airway available, have emergency cricothyroidotomy kit available)</p> <p>If Cesarean delivery Bariatric surgery should not be considered an indication for CD Anticipate greater time from incision to delivery Pfannenstiel incision carries less risk of infection and dehiscence than midline incision Consider retracting panniculus cephalad (or caudad) with tape or large “loban” drape Consider self-retaining retractor, extra-long instruments Close subcutaneous layer (34% decrease in wound disruption) Subcutaneous drains may be associated with a higher risk of infection Consider closure with polydioxanone (PDS) Consider Smead-Jones “mass closure” If staples used for skin closure, do not remove until 7-10 days postoperatively for a vertical incision and 5 days for a Pfannenstiel Increase dose of prophylactic cefazolin to 3 g IV before incision if BMI > 40 kg/m² Panniculectomy at the time of CD increases complications Early ambulation Intermittent pneumatic compression devices Consider using bariatric bed with frame and trapeze for mobility postoperatively Anticoagulation if 1 major or 2 minor ACP risk factors for VTE Enoxaparin 40mg every 12 hours for BMI < 50 kg/m², 60 mg every 12 hours for BMI > 50 kg/m² or weight based dosing (e.g., enoxaparin 0.5 mg/kg every 12 hours)</p>
<p>Obesity in Pregnancy Guideline ⁴</p>	<p>9.2020</p>	<p>National Health System Northern Devon Healthcare United Kingdom https://www.northdevo</p>	<p>Care Pathway</p>	<p>Intrapartum All blood pressure measurements should be taken using the appropriate size arm cuff. Complete a manual handling risk assessment to ensure the correct equipment is available and used</p>

36/bmjopen-2022-061433 Downloaded from <http://bmjopen.bmj.com/> on April 20, 2023 by guest. Protected by copyright.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

36/bmjopen-2022-011330 on 15 September 2022. Downloaded from <http://bmjopen.bmj.com/>. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

		nhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf		<p>Measure and fit TED anti-embolism stockings. Consider calf compression device for all women with BMI ≥ 40. Assess pressure areas and maintain skin integrity. Consider ultrasound scan to confirm fetal presentation. Be alert to increased risk of shoulder dystocia. The duty anaesthetist and duty obstetric registrar should be informed when a woman with a BMI ≥ 40 is admitted to labour ward. Women with a BMI ≥ 40 should have IV access early in labour with "FBC and group and save taken". For women with a BMI ≥ 40, prophylactic omeprazole should be administered as per prescription. Raised BMI alone is not an indication for continuous fetal monitoring in labour. Postpartum All women with a BMI ≥ 35 should be recommended to have active management of the third stage of labour Women with a BMI ≥ 30 should be encouraged to mobilise as early as practicable following childbirth to reduce the risk of thromboembolism. TED stockings or calf compression devices to be worn throughout hospital stay regardless of mode of delivery for women with BMI ≥ 35. Assess wound and observe for signs of dehiscence.</p>
<p>Obesity in Pregnancy, Labour and Puerperium ⁵</p>	<p>2019</p>	<p>University Hospitals of Leicester NHS Trust United Kingdom Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk)</p>	<p>Guideline</p>	<p>Intrapartum: Assessment of tissue viability by completing "Waterlow Risk Assessment Form"; if value > 10 then inspect skin daily via "BEST SHOT" guidance (also postpartum) Notify OR staff on admission if weight > 140 kg Postpartum: Early mobilization Use compression stocking if ≥ 2 risk factors VTE prophylaxis for 7 days if ≥ 1 risk factors If BMI ≥ 40: Early IV access Consider early epidural Experienced obstetrician (\geq ST6) to perform CD or "rotational instrumental delivery" Active management of 3rd stage Consider IV syntocinon instead of IM route</p>

				VTE prophylaxis regardless of delivery route Consider increased dose of antibiotic prophylaxis
Obesity Medicine Management of obesity in women's health care. Chapter 19: Checklists for Care: Care Maps for Pregnancy in the Obese Gravida ⁶	2017	United States	CareMap	Intrapartum Obtain clear fetal heart tracing and uterine contraction assessment Place SCD Early consultation with anesthesia Confirm adequate equipment for anesthesia, labor and delivery, and operating room Discuss/plan for the following: delivery route, skin cleansing/preparation, antibiotic dosing for CD (consider 3g cefazolin if weight > 120 kg), postpartum VTE prophylaxis (SCD, LMWH), early ambulation, perineal laceration or incision care, address medical comorbidities, medication adjustments Immediate postpartum VTE prophylaxis Early ambulation Anticoagulation (if indicated) Lactation referral
Supporting a Plus- Size Pregnancy: A Checklist for Healthcare Providers ⁷	2019	United States NIH/NICHD, National Child and Maternal Health Education Program NIH Pub.Number: 19- HD-8100 https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf	Checklist	Ensure availability of appropriate birthing beds and monitoring/other equipment to care for plus-size patients (e.g., large chairs and wheelchairs, larger blood pressure cuffs). Assess appropriateness of gurneys and staffing plans and revise as needed (e.g., get motorized lifts for gurneys, increase staff to assist with moving the patient). Consider consulting with an anesthesia service, especially for patients with obstructive sleep apnea, in case the need for a surgical delivery arises. Consider early epidural catheter placement, and discuss the risks and benefits with the patient. Consider allowing a longer first stage of labor before performing cesarean delivery for labor arrest. Work with your patient to create a birthing plan, including pain management methods. Work with your patient to create a breastfeeding plan and help her get lactation support/consultation, if needed.
Antenatal Management of Obesity ⁸	2018	Spectrum Health Medical Group Michigan, United States	Protocol	Anesthesia consult if BMI > 60 Prophylactic antibiotics "Azithro + Ancel" (3g if >120kg)" Delivery timing 39-40 weeks

36/bmjopen-2022-014300 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		www.spectrumhealth.org/mfm/protocol-obesity		Consider wound vac placement post op if Class III obesity with risk factors (DM, chorio) or BMI > 60 Postop prophylactic lovenox while inpatient for class I and II obesity with risk factors, >= class III regardless of risk factors
--	--	--	--	---

Appendix B: Title, year of publication, source of recommendations, and content topic for tools for the peripartum management of obesity identified from searches of Google Scholar.

^a During original Google scholar search on 4.1.21, the Queensland Clinical Guideline for “Obesity in pregnancy” was published in 2015. When the manuscript was updated for publication, a new version of the guideline was published in 8.2021 and therefore the most recent guideline was used for this manuscript since the prior link was no longer available.

IOL induction of labor

CD or CS cesarean delivery

IV intravenous

BMI body mass index

PPH postpartum hemorrhage

VTE venous thromboembolism

TOLAC trial of labor after cesarean

IUPC intrauterine pressure catheter

FSE fetal scalp electrode

PDS polydioxanone

1
2
3 ACCP American College of Chest Physicians
4

5 TED thrombo-embolus deterrent
6

7 OR operating room
8

9 NIBP non-invasive blood pressure
10

11 BP blood pressure
12

13 NB neuraxial blockade
14

15 LMWH low molecular weight heparin
16

17 DM diabetes
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Reference List for Appendix B

1. Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg> Accessed 9/24/21.
2. Gynecology UoNMSoMDoOa. Standard operating procedure-guideline class 3 obesity and pregnancy <http://unmobgyn.pbworks.com/w/file/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf> 2020 [
3. Obesity in pregnancy - ANMC guideline Alaska Native Medical Center [Available from: <https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf>
4. Obesity in pregnancy guideline National Health System Northern Devon Healthcare2020 [Available from: <https://www.northdevonhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf>.
5. Obesity in pregnancy, labour and the puerperium University Hospitals of Leicester NHS Trust2019 [Available from: Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk).
6. RK S. Obesity Medicine: Management of Obesity in Women's Health Care 1ed: McGraw-Hill Education; 2017.
7. Supporting a plus-size pregnancy: a checklist for healthcare providers NIH Pub.Number: 19-HD-8100: Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2019 [Available from: https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf.
8. Antenatal management of obesity: Spectrum Health The Medical Group Maternal Fetal Medicine; 2018 [Available from: www.spectrumhealth.org/mfm/protocol-obesity.

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	3
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Cover letter
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	4
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	4, Appendix A
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix A
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	4
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	5
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	5



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	5
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	5, figure 1
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	6, Table 1,2,Appendix B
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	6-7
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	6-7
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	8
Limitations	20	Discuss the limitations of the scoping review process.	10
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	9, Table 3
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Title page

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).



St. Michael's

Inspired Care.
Inspiring Science.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Peripartum care of persons with obesity: A scoping review of recommendations and practical tools for implementation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061430.R2
Article Type:	Original research
Date Submitted by the Author:	26-Aug-2022
Complete List of Authors:	Kominiarek, Michelle A. ; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Cassimatis, Irina; Northwestern University, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine Peace, Jack; Temple University Lewis Katz School of Medicine, Department of Anesthesiology Premkumar, Ashish ; Northwestern University, Obstetrics and Gynecology; John H Stroger Hospital of Cook County, Obstetrics and Gynecology Toledo, Paloma ; Northwestern University Feinberg School of Medicine, Anesthesiology O'Dwyer, Linda; Northwestern University, Obstetrics and Gynecology
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Evidence based practice
Keywords:	OBSTETRICS, Maternal medicine < OBSTETRICS, PERINATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Title Page
4

5 Peripartum care of persons with obesity: A scoping review of recommendations and
6
7 practical tools for implementation
8
9

10 Michelle A. KOMINIAREK, MD, MS¹ mkominia@nm.org
11

12 Irina CASSIMATIS, MD, MSc¹ irina.cassimatis@northwestern.edu
13

14 Jack M. PEACE, MD² jackpeace5@gmail.com
15

16 Ashish PREMKUMAR, MD^{1,3} ashish.premkumar@northwestern.edu
17

18 Paloma TOLEDO, MD, MPH⁴ p-toledo@northwestern.edu
19

20 Linda C. O'DWYER, MA, MSLIS⁵ l-odwyer@northwestern.edu
21

22
23
24 1 Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine,
25
26 Northwestern University Feinberg School of Medicine; Chicago, IL
27

28
29 2 Department of Anesthesiology, Temple University Lewis Katz School of Medicine;
30
31 Philadelphia, PA
32

33 3 Department of Obstetrics and Gynecology, John H Stroger Hospital; Chicago IL
34

35 4 Department of Anesthesiology, Northwestern University Feinberg School of Medicine;
36
37 Chicago, IL
38

39
40 5 Galter Health Sciences Library & Learning Center, Northwestern University Feinberg
41
42 School of Medicine; Chicago, IL
43

44 The scoping review protocol is published at <https://doi.org/10.18131/g3-gyms-ww23>.
45

46 (PROSPERO does not accept protocols for scoping reviews.)
47

48
49 This study was presented in poster format at the Society for Maternal-Fetal Medicine
50
51 Annual Meeting in Orlando, Florida. January 31, 2022 - February 5, 2022.
52

53
54 Corresponding author:
55
56
57
58
59
60

1
2
3 Michelle A. Kominiarek, MD MS

4
5 Department of Obstetrics and Gynecology

6
7 Associate Professor, Northwestern University Feinberg School of Medicine

8
9
10 250 East Superior Street

11
12 Suite 05-2154

13
14 Chicago, IL 60611

15
16 (312)472-6747

17
18 mkominia@nm.org

19
20
21 Abstract word count 299

22
23
24 Main text word count 3238

Abstract

Objective: Despite the growing prevalence of obesity among reproductive aged persons in the U.S., evidence-based guidelines for peripartum care are lacking. The objective of this scoping review is to identify obesity-related recommendations for peripartum care, evaluate grades of evidence for each recommendation, and identify practical tools (e.g., checklists, toolkits, care pathways, bundles) to support their implementation in clinical practice.

Data sources: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from inception to December 2020 for eligible studies addressing peripartum care in persons with obesity.

Study eligibility criteria: Inclusion criteria were published evidence-rated recommendations and practical tools for peripartum care of persons with obesity.

Study appraisal and synthesis methods: Pairs of independent reviewers extracted data (source, publication year, content and number of recommendations, level and grade of evidence, description of tool) and identified similarities and differences among the articles.

Results: Of 18,315 screened articles, 18 were included including 7 articles with evidence-rated recommendations and 11 practical tools (3 checklists, 3 guidelines, 1 care bundle, 1 flowchart, 1 care pathway, 1 care map, 1 protocol). Thirteen of 39 evidence-rated recommendations were based on expert opinion. Recommendations related to surgical antibiotic prophylaxis and subcutaneous tissue closure at cesarean delivery received the highest-grade of evidence. Some of the practical tools included a

1
2
3 checklist from the United States regarding anticoagulation after cesarean delivery
4
5 (evidence supported recommendation), a bundle for surgical site infections after
6
7 cesarean delivery in Australia (evidence did not support recommendation), and a
8
9 checklist with content for several aspects of peripartum care from Canada (evidence
10
11 supported seven of nine definitive recommendations).
12
13
14

15
16 Conclusion: The recommendations for peripartum care for persons with obesity are
17
18 based on limited evidence and few practical tools for implementation exist. Future work
19
20 should focus on developing practical tools based on high quality studies.
21
22

23 Strengths and limitations of this study:

- 24
25
26
- 27 • We may not have identified all articles with evidence-rated recommendations,
28 though our search of available published literature was thorough including a
29 search of appropriate web sites.
30
31
 - 32 • Sites may have practical implementation tools that they use in the short- or long-
33 term, but they may not be published or available in a more public domain.
34
35
 - 36 • Although topics such as contraception and postpartum weight management are
37 important in the postpartum care of persons with obesity, they were not
38 specifically addressed in this review, which pertained to peripartum care in the
39 immediate postpartum period.
40
41
 - 42 • Obesity was typically defined according to a BMI ≥ 30.0 kg/m², but in many
43 instances the timing of the BMI was not provided (e.g., pre-pregnancy vs. at
44 delivery).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- We did not include recommendations that were intended for patient education only in this review.

Keywords: obesity, peripartum care, pregnancy, tools

For peer review only

INTRODUCTION

Obesity has reached epidemic proportions in the United States.[1] In 2015-2016, non-Hispanic Black (54.8%) and Hispanic (50.6%) women had the highest prevalence of obesity and 36.5% of reproductive age women (20-39 years) had obesity (BMI \geq 30.0 kg/m²), translating to a high percentage of persons with obesity during future pregnancies and race-ethnicity health disparities.[2] Of further concern, over 50% of persons with obesity exceed guidelines for weight gain during pregnancy, thus compounding their risks for adverse outcomes.[3-5] Adverse peripartum outcomes associated with obesity include cesarean delivery, infection, hemorrhage, thromboembolism (VTE), and anesthesia-related complications, such as failure of regional anesthesia and respiratory depression.[6] These adverse outcomes are amplified in persons with a BMI \geq 50 kg/m². [7] Furthermore, obesity is cited as a contributing factor in over 50% of maternal deaths.[8]

Adaptations to prenatal care for persons with obesity include early screening for diabetes and limiting weight gain to 11-20 pounds.[9] However, more evidence-based studies for peripartum care of persons with obesity, where the risk for adverse outcomes is a significant concern, are needed. For example, the National Institute for Health and Care Excellence (NICE) performed evidence-based reviews for the intrapartum management of obesity in 2019 and found no clinical evidence to suggest that the management of fetal monitoring or maternal positioning in labor should be altered.[10] Even fewer studies and evidence-based recommendations are available for those with a BMI \geq 50 kg/m², who are at even higher risk for adverse outcomes.

1
2
3 Strategies that have reduced adverse outcomes in obstetrics include the development
4 of checklists or toolkits after identifying patient, provider, and systems factors for
5 improvement in the care pathway.[11] Given the increasing incidence of obesity and
6 obesity-related complications, it is critical to identify opportunities to improve the safe
7 delivery of peripartum care.
8
9
10
11
12
13

14 **Objectives**

15
16 The objective of this scoping review is to identify obesity-related recommendations for
17 peripartum care, evaluate levels or grades of evidence for each recommendation, and
18 identify practical tools such as checklists, toolkits, or other comprehensive care
19 pathways to support their implementation in clinical practice. In this scoping review, we
20 were specifically interested in recommendations that pertained to actionable items such
21 as a treatment or decision option or a specialized consultation.
22
23
24
25
26
27
28
29
30
31
32

33 **METHODS**

34 **Eligibility criteria, information sources, search strategy**

35 The PRISMA extension for scoping reviews (PRISMA-ScR) checklist was used in
36 developing and reporting this scoping review.[12] The inclusion criteria were: (1)
37 published (in print or online) recommendations along with levels or grades of evidence
38 for the peripartum care of persons with obesity (BMI \geq 30.0 kg/m²), and if possible,
39 specifically for persons with a BMI \geq 50 kg/m²; or (2) published (in print or online)
40 description of a tool such as a checklist, toolkit, or comprehensive care pathway for the
41 peripartum care of obesity. We defined peripartum care to refer to care immediately
42 before, during and after delivery, approximately 24 hours before and after delivery. To
43 be included in the review, the identified recommendations needed to focus on
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 actionable items or management strategies, as opposed to being a listing of
4
5 comorbidities or risks that are associated with obesity in pregnancy. Actionable items
6
7 might include giving or withholding a particular medication or device. Recommendations
8
9 that exclusively related to “patient counseling” or imparting of knowledge to the patient
10
11 were not included as the interpretation of counseling can have different meanings
12
13 depending on the clinical setting (e.g., location of clinical practice, provider type). The
14
15 recommendations could have been abstracted from articles pertaining to obesity alone,
16
17 or other articles that specified recommendations pertaining to obesity (e.g., antibiotic
18
19 use in pregnancy with a specific adaptation for persons with obesity). Because
20
21 recommendations could be published from varying health care systems and there were
22
23 no restrictions placed on country of origin (e.g., national guidelines from United States
24
25 vs. United Kingdom), variances in evidence grading were identified and abstracted
26
27 according to the health care system’s grading method.
28
29
30
31
32

33 We searched PubMed MEDLINE, Embase (embase.com), Cochrane Central Register
34
35 of Controlled Trials (Wiley), CINAHL (EbscoHost), and clinicaltrials.gov from inception
36
37 through December 2020, with no date or language restrictions. The search for eligible
38
39 studies involved controlled vocabulary (MeSH headings and thesauri of relevant
40
41 databases) and the keywords of obesity, morbid obesity, super morbid obesity,
42
43 guidelines, recommendations, checklist, toolkit, maternal care pathway, peripartum
44
45 care, and pregnancy. The bibliographies of relevant reviews were hand-searched, as
46
47 well as key websites including Google Scholar. A full list of the sources and search
48
49 strategies is outlined in Appendix A.
50
51
52
53

54 **Patient and Public Involvement**

55
56
57
58
59
60

1
2
3 Patients were not directly involved in the design of this study.
4
5

6 **Study Selection**

7 The questions for this scoping review were: (1) What are the recommendations for
8 peripartum care of persons with obesity published by either individual authors, national
9 societies, or other government departments that provide levels or grades of evidence to
10 support the recommendation? (2) What are the published tools for practical
11 implementation of recommendations, either in the form of checklists, toolkits, or other
12 comprehensive care pathways?
13
14
15
16
17
18
19
20
21

22 The primary outcomes were the number of recommendations per article, topic of
23 recommendation, level or grade of evidence to support recommendations, and
24 similarities and differences between the recommendations across articles. For the
25 identified checklists, toolkits, or other comprehensive care pathways for the peripartum
26 management of obesity, their details were summarized and crosschecked with the
27 aforementioned recommendations.
28
29
30
31
32
33
34
35

36 **Data extraction**

37 Four reviewers independently screened all citations using the Covidence review
38 management software.[13] Initially, the reviewers were trained on a sample of 20
39 articles using the Covidence software to verify clarity and consistency regarding
40 inclusion and exclusion criteria. A separate, 5th reviewer resolved all conflicts. Once
41 agreement was obtained on articles meeting criteria for final inclusion, two reviewers
42 independently extracted the following data from each article using a form that was
43 tested and modified by the reviewers, as applicable: (1) source of recommendations
44 (e.g., individual authors, national societies, etc.), (2) year of publication, (3) content and
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

total number of recommendations, (4) level and grade of evidence for each of the recommendations, (4) system used to determine levels of evidence or classification of recommendations, (5) description of checklist, toolkit, comprehensive care pathway or other format used for implementation in the peripartum care of obesity. If articles were in abstract form only, we contacted the authors for updates on the status of the final publication.

Data synthesis

The data were summarized and abstracted into table format, noting key similarities and differences among the articles in terms of content and level and grade of evidence. For the identified checklists, toolkits, etc. similarities and differences among the content were highlighted. For this scoping review, we did not assess the effectiveness of the findings or evaluate bias. The scoping review protocol is published at <https://doi.org/10.18131/g3-gyms-ww23>.

RESULTS

Study selection

After removal of duplicates, 18,328 articles were screened, resulting in 203 articles for full-text review. Figure 1 shows the flow diagram for study selection. A total of 7 evidence-rated articles and 11 tools met inclusion criteria for this review. The majority (n=8) of the tools were selected from the results of Google Scholar searches.

Study characteristics

Table 1 displays the title, year of publication, source of recommendations, and references for evidence levels and grades for seven articles identified from the search of all databases. The publication years ranged from 2015-2020 representing three

countries (US, UK, Canada) and one international guideline. Publication topics included thromboembolism, antibiotics prophylaxis, as well as the broad-spectrum of peripartum care. For these articles, the content was either exclusively focused on the management of obesity or the content was about a high-risk condition during pregnancy and addressed obesity among other issues. Table 2 displays the topic, content of the recommendation, and evidence levels and grades for each recommendation from the seven articles in Table 1. For the tools, Table 3 displays the title, year of publication, source of recommendations, and content topic for the peripartum management of obesity identified from searches of PubMed MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and CINAHL (n=3). Appendix B displays the same information identified from a search of key websites and Google Scholar for tools (n=8). We found a wide range of tools including checklists, bundles, flow charts, guidelines, protocols, care pathways, and care maps from practices in the United States, Canada, and the United Kingdom.

Table 1. Source of recommendations, year of publication, title, evidence grading system and levels and grades for 7 articles related to peripartum management of obesity

Author/Source	Date	Title	Evidence Grading System Examples of grade and level ranges
McAuliffe et al International Federation of Gynecology and Obstetrics	2020	Management of prepregnancy, pregnancy, and postpartum obesity[14]	GRADE[15] Grade strong or weak Evidence low, moderate, high or best practice
Society for Maternal-Fetal Medicine (United States); 1/6 recommendations pertain to obesity	2020	SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery[16]	GRADE[15] Grade strong or weak Evidence low, moderate, high or best practice
J van Schalkwyk, N Van Eyk Society of Obstetricians and Gynaecologists of Canada (Canada); 1/7 recommendations pertain to obesity	2017	Guideline No. 247-Antibiotic prophylaxis in obstetric procedures[17]	Canadian Task Force on Preventive Health Care [18] Levels I-III Classifications A-I

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Maxwell C, et al. Society of Obstetricians and Gynaecologists of Canada (Canada)	2019, 2020 correction	Guideline No. 392-Pregnancy and maternal obesity Part 2: Team planning for delivery and postpartum care[19]	Canadian Task Force on Preventive Health Care [18] Levels I-III Classifications A-E,I
Denison FC, et al. Royal College of Obstetricians and Gynaecologists (United Kingdom)	2018	Care of women with obesity in pregnancy Green-top Guideline #72[20]	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines [21] Grades A-D, and "checkmark" Levels 1++ to 4
Royal College of Obstetricians and Gynaecologists (United Kingdom)	2015	Reducing the risk of venous thromboembolism during pregnancy and the puerperium Green-top Guideline No.37a[22]	Clinical Governance Advice No.1 Development of RCOG Green-Top Guidelines [21] Grades A-D, and "checkmark" Levels 1++ to 4
American College of Obstetricians and Gynecologists Practice Bulletin (United States)	2015	Practice Bulletin #156 Obesity in pregnancy[9]	U.S. Preventive Services Task Force [23] Grade A-C Levels I-III

GRADE Grading of Recommendations Assessment, Development and Evaluation

SMFM Society for Maternal-Fetal Medicine

RCOG Royal College of Obstetricians and Gynaecologists

Table 2. Topics, recommendations, and level or grade of evidence among 7 articles related to peripartum management of obesity.

Topic	Recommendation	Level or grade of evidence
Route of delivery	The decision for a woman with maternal obesity to give birth by planned caesarean section should involve a multidisciplinary approach, taking into consideration the individual woman's comorbidities, antenatal complications and wishes.[20]	Level 2-, C
Labor induction	Induction of labor is recommended at 41+0 weeks of gestation for women with a BMI \geq 35 owing to their increased risk of intrauterine death.[14]	Strong + + +
	Elective induction of labour at term in obese women may reduce the chance of caesarean birth without increasing the risk of adverse outcomes.[20]	Level 2+, B
	Where macrosomia is suspected, induction of labour may be considered. Parents should have a discussion about the options of induction of labour and expectant management.[20]	Level 1+, B
Fetal monitoring	Electronic fetal monitoring is recommended for women in active labor with a BMI \geq 35. Intrauterine pressure catheters and fetal scalp electrodes may help.[14]	Conditional +
	(a) Electronic fetal monitoring can be considered for women in active labour with a body mass index $>$ 35 kg/m ² . (b) Intrauterine pressure catheters may assist in assessment of labour contractions. (c) Fetal scalp electrodes may be helpful to ensure continuous fetal monitoring when indicated.[19]	III-B
Labor management	Allowing a longer first stage of labor before performing cesarean delivery for labor arrest should be considered in obese women.[9]	B, Level II-2,3
Blood pressure monitoring	Where available, an appropriately sized blood pressure cuff should be used for measurements. The cuff size used at the earliest time point should be documented in the medical records.[14]	Conditional ++
IV access	Establish venous access in early labor for women with a BMI \geq 40 and consider a second cannula.[14]	Conditional +
	Women with a BMI 40 kg/m ² or greater should have venous access established early in labour and consideration should be given to the siting of a second cannula.[20]	Checkmark
Regional anesthesia	In the case of vaginal delivery for women with a BMI \geq 40, early placement of an epidural catheter is advisable in the case of an emergency cesarean delivery.[14]	Conditional + +
Antibiotic prophylaxis for cesarean delivery	Women with a BMI \geq 30 having a cesarean delivery are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery. Women with obesity may benefit from higher doses.[14]	Strong + + + +
	In patients with morbid obesity (BMI $>$ 35), doubling the antibiotic dose may be considered.[17]	III-B
	Women with obesity may benefit from higher dosage of preoperative antibiotics for caesarean birth.[19]	I-A
	Women with class 1 obesity or greater having a caesarean section are at increased risk of wound infection and should receive prophylactic antibiotics at the time of surgery.[20]	Level 1++, A
Incision type, skin closure for cesarean delivery	There is a paucity of high-quality evidence to support the use of one surgical approach over another. Surgical approaches should therefore follow NICE CG132 but clinicians may decide alternative approaches are merited depending on individual circumstances.[20]	Checkmark
Subcutaneous tissue closure	It is recommended to reapproximate the subcutaneous tissue layers at the time of caesarean birth to reduce wound complications.[19]	II-2A
	Women undergoing caesarean section who have more than 2 cm subcutaneous fat should have suturing of the subcutaneous tissue space in order to reduce the risk of wound infection and wound separation.[20]	Level 1++, A

Topic	Recommendation	Level or grade of evidence
	Subcutaneous drains increase the risk of postpartum cesarean wound complications and should not be used routinely.[9]	Grade A, Level 1
	There is a lack of good-quality evidence to recommend the routine use of negative pressure dressing therapy, barrier retractors and insertion of subcutaneous drains to reduce the risk of wound infection in obese women requiring caesarean sections.[20]	Level 2- to 1+, B
Hemorrhage	Active management of the third stage should be recommended to reduce the risk of postpartum hemorrhage.[14]	Strong + + +
	Although active management of the third stage of labour is advised for all women, the increased risk of PH in those with a BMI greater than 30 kg/m ² makes this even more important.[20]	Level 2++, A or Level 1++, B ^a
VTE prophylaxis	Postoperative pharmacologic thromboprophylaxis should be prescribed based on maternal weight.[14]	Conditional + +
	Mechanical thromboprophylaxis is recommended before and after cesarean delivery. Where available, women with a BMI ≥ 35 should be given graduated compression stockings, or other interventions such as sequential compression devices, after cesarean delivery until mobilization, which should be encouraged early.[14]	Conditional + +
	When pharmacologic thromboprophylaxis is needed in pregnant women with class III obesity, we suggest the use of intermediate doses of enoxaparin [for cesarean delivery].[16]	2C
	Postoperative thromboprophylaxis is recommended, at appropriate dosing for the given body mass index due to the greater risk of venous thromboembolism following caesarean birth with women with obesity.[19]	II-3 A
	All women with class 3 obesity (BMI greater than or equal to 40 kg/m ²) should be considered for prophylactic LMWH in doses appropriate for their weight for 10 days after delivery.[22]	D
	Women with two or more persisting risk factors listed in Table 1 should be considered for LMWH in prophylactic doses appropriate for their weight for 10 days after delivery. One risk factor = BMI ≥ 30kg/m ² . [22]	B
	Mechanical thromboprophylaxis is recommended before cesarean delivery, if possible, as well as after cesarean delivery.[9]	B, Level II-3
	Weight-based dosage for venous thromboembolism thromboprophylaxis may be more effective than BMI stratified dosage strategies in class III obese women after cesarean delivery.[9]	B, Level II-3
Breastfeeding	Obesity is associated with low breastfeeding initiation and maintenance. Women with obesity in early pregnancy should receive specialist advice on the benefits of breastfeeding and appropriate antenatal and postnatal support for breastfeeding initiation and maintenance.[14]	Conditional + +
	Women with obesity should be offered lactation support in the postpartum period.[19]	III C
	Obesity is associated with low breastfeeding initiation and maintenance rates. Women with a booking BMI ≥ 30 kg/m ² or greater should receive appropriate specialist advice and support antenatally and postnatally regarding the benefits, initiation and maintenance of breastfeeding.[20]	Checkmark, Level 1+
Anesthesiology consult	Antenatal assessment with obstetric anaesthesia may assist in planning for safer birth for women with obesity.[19]	III-A
	The on-duty anaesthetist covering the labour ward should be informed of all women with class III obesity admitted to the labour ward for birth. This communication should be documented by the attending midwife in the notes.[20]	Checkmark
Systems	Where possible, healthcare facilities should have clearly defined pathways for the management of pregnant women with obesity. The adequacy of resources and equipment available should be considered when making decisions around care, especially for women with a BMI ≥ 40.[14]	Conditional +
	Obstetric team planning may be helpful for women with obesity to navigate the steps in antenatal, labour and delivery, and postnatal care.[19]	III-3 A ^b

36/bmjopen-2022-061430 on 1 September 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Topic	Recommendation	Level or grade of evidence
	Consultation with anesthesia service should be considered for obese pregnant women with OSA because they are at an increased risk of hypoxemia, hypercapnia, and sudden death.[9]	C

^a The recommendation is reports as “Level 2++, A” on page 26 of the document and also reported as “Level 1++, B” on pages 8 and 30 of the document.

^b The recommendation is reported as “III-3 A”, though this level and grade of evidence is not defined in the Society of Obstetricians and Gynaecologists of Canada document.

BMI body mass index

NICE CG National Institute for Health and Care Excellence Clinical Guidelines

VTE venous thromboembolism

PPH postpartum hemorrhage

IV intravenous

LMWH low molecular weight heparin

OSA obstructive sleep apnea

Table 3: Title, year of publication, source of recommendations, content topic, and evidence to support recommendation among 3 tools related to the peripartum management of obesity

Title	Year	Source or Site	Tool type	Content	Evidence to support content when a definitive recommendation was made in the tool
Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery[24]	2020	Society for Maternal-Fetal Medicine	Checklist	VTE prophylaxis (after cesarean delivery) For women with body mass index (BMI) 40 kg/m ² or greater (class 3 obesity) who have thrombophilia or history of deep venous thrombosis or pulmonary embolism, intermediate-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg SC every 12 hours); continue for 6 weeks postoperatively	SMFM[16] Level 2C
Reducing surgical site infections post-cesarean section in an Australian hospital, using a bundled care approach[25]	2020	NSW Local Health District, Australia	Bundle	Subcutaneous tissue closure Negative pressure wound therapy BMI>35 (PICO) BMI > 40 (Prevena) applied in operating suite at the time of incision closure and left in-situ for 7 days	RCOG[20] Level 2- to 1+, B does NOT support recommendation
Team Planning in Obstetrical Care for Women with Obesity[26]	2019	Mount Sinai Hospital in Toronto, Ontario Canada	Checklist	General admission for delivery PICC line recommended (checkbox) Intrapartum Type of delivery (spontaneous or induced labor or Cesarean delivery) (checkbox) Appropriate size [blood pressure] cuff Appropriate size gown, long monitoring belts Notify OB, Anesthesia, Respiratory therapist, Neonatology May need cross and type IUPC use (checkbox) Encourage ambulation Cesarean delivery	FIGO[14] Conditional ++ for BP cuff size RCOG[20] “Checkmark” for notify anesthesia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

				<p>Incision location</p> <p>Method of [incision] closure</p> <p>Use of negative pressure wound system (checkbox).</p> <p>Plan for prolonged length of stay if OSA/CPAP (checkbox)</p> <p>Additional medication for gastric emptying/GERD and possible additional antibiotics</p> <p>Equipment (OR table with side bars and pads, OR tray, hover mat, epidural/spinal needle and portable ultrasound, Troop pillow, need for difficult airway try, Mobius retractor and Sturgeon, Traxi Panniculus retractor, negative pressure wound system)</p> <p>Need for increased length of stay due to anesthesia (checkbox) (e.g., CPAP for sleep apnea).</p> <p>Postpartum</p> <p>Bariatric bed required for a weight > 500 lbs. (check box)</p> <p>Delay in suture or staple removal with the postoperative day entered for removal as an outpatient.</p> <p>Prophylactic anticoagulation, early ambulation encouraged</p> <p>Pain management plan with dosage changes</p> <p>Breastfeeding, lactation consultant</p> <p>Dietician follow-up</p>	<p>SOGC[17, 19] Level 1-A and Level III-B for additional antibiotics</p> <p>FIGO[14] Conditional 1+ for resources an equipment</p> <p>FIGO[14] Conditional 1+ for resources an equipment</p> <p>None</p> <p>SMFM[16] Level 2C, FIGO Conditional ++[14], SOGC[19] II-3, RCOG[20] Grade B or D, ACOG[9] Grade B Level 2, 3</p> <p>None</p> <p>FIGO[14] Conditional ++, RCOG[20] "checkmark", Level 1+</p>
--	--	--	--	---	---

SMFM Society for Maternal-Fetal Medicine

BMI body mass index

SC subcutaneous

36/bmjopen-2022-061430 on 19 September 2022. Downloaded from <http://bmjopen.bmj.com/> on 19 September 2022 by guest. Protected by copyright.

1
2
3 NSW North South Wales

4
5 RCOG Royal College of Obstetricians and Gynecologists

6
7 PICC peripherally inserted central catheter

8
9 BP blood pressure

10
11 OB obstetrics

12
13 IUPC intrauterine pressure catheter

14
15 OSA obstructive sleep apnea

16
17 CPAP continuous positive airway pressure

18
19 FIGO International Federation of Gynecology and Obstetrics

20
21 SOCG Society of Obstetricians and Gynaecologists of Canada

22
23 OR operating room

24
25 VTE venous thromboembolism

26
27 ACOG American College of Obstetricians and Gynecologists

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Synthesis of Results

The evidence-rated recommendations covered topics such as labor induction (e.g., indication and timing), intravenous access, fetal monitoring (e.g., scalp electrodes, intrauterine pressure catheters), management of the 1st and 3rd stages of labor, breastfeeding, and system-related preparedness. Several recommendations were specific to cesarean delivery (e.g., incision type, antibiotic prophylaxis and dose, subcutaneous tissue closure, negative pressure dressings, and VTE prophylaxis) and anesthesia (e.g., consultation, early placement of an epidural catheter). In several instances, recommendations for persons with obesity did not differ from recommendations for persons without obesity (e.g., antibiotic prophylaxis for cesarean delivery).[20] Three articles had one recommendation [16, 17, 22] and the highest number of recommendations was 11 in a single article.[14] The FIGO (International Federation of Gynecology and Obstetrics) Pregnancy and Non-Communicable Disease Committee published guidelines for the management of pre-pregnancy, pregnancy, and postpartum obesity. Their recommendations for peripartum management (n=11) were included in this analysis, but it should be noted that the recommendations were not unique to the article, but instead they were abstracted from previously published international articles.[14]

The recommendations that were of the highest grade (Strong, Level 1, or Grade A) were antibiotic prophylaxis for cesarean delivery,[14, 20] higher dosage of preoperative antibiotics for cesarean delivery,[17, 19] and subcutaneous tissue closure.[9, 20] We noted that 13 recommendations were based on expert opinion or the lowest level of evidence. We noted that topics such as antibiotic prophylaxis (n=4

1
2
3 recommendations),[14, 17, 19] subcutaneous skin closure (n=4 recommendations),[9,
4
5 19, 20] and VTE prophylaxis (n=8 recommendations)[9, 14, 16, 19] were most
6
7 commonly addressed. There were two instances where a particular intervention was not
8
9 recommended (e.g., subcutaneous drains, negative pressure dressing therapy).[9, 20]
10
11 We did not find any recommendations that directly opposed one other, but there were
12
13 differences in the specifics of the recommendations. For example, the American College
14
15 of Obstetricians and Gynecologists (ACOG) recommends an anesthesiology consult for
16
17 persons with both obesity and obstructive sleep apnea whereas RCOG recommends
18
19 that the anesthetist “be informed of all women with class III obesity”.[9, 20] In one
20
21 guideline from the Society of Obstetricians and Gynaecologists of Canada (SOGC), the
22
23 recommendation is for a “higher” dose [19] and another recommendation from the
24
25 SOGC is for a “double dose” [17] of antibiotic prophylaxis. Regarding specific
26
27 recommendations for persons with different classes of obesity, we only found
28
29 recommendations for weight-based VTE prophylaxis dosing [9, 16, 22] and
30
31 anesthesiology consultations.[20]
32
33
34
35
36
37

38 Regarding the practical tools for implementation (Table 3), the style varied. In a
39
40 checklist and bundle, there were specific recommendations including “40 mg of
41
42 enoxaparin subcutaneously twice daily for VTE prophylaxis after cesarean delivery” [24]
43
44 and “negative pressure wound therapy...applied in operating suite at the time of incision
45
46 closure and left-in-situ for 7 days”, respectively.[25] Another checklist had several
47
48 recommendations for intrapartum and postpartum care with check boxes (e.g.,
49
50 intrauterine pressure catheter use, incision type, negative pressure dressing therapy),
51
52 ultimately leaving the decision to perform the intervention or not up to the individual
53
54
55
56
57
58
59
60

1
2
3 provider.[26] Common terms found in the tools from Google Scholar searches included
4
5 “consider” a certain treatment option or “anticipate” a particular complication (Appendix
6
7 B). We noted differences in these tools for continuous fetal monitoring, where two tools
8
9 recommend continuous fetal monitoring,[27, 28] but one did not.[29] In addition, two
10
11 tools [25, 30] recommended negative pressure dressing therapy for certain
12
13 circumstances (e.g., BMI > 35 kg/m² or > 40 kg/m²) whereas another tool stated “avoid
14
15 the use of wound vacs.”[27]
16
17

18
19 We then evaluated the similarities and differences between the evidence-rated
20
21 recommendations in Table 2 and any of the published tools in Table 3. The evidence to
22
23 support or not support the content in the tools from Table 2 was provided in the last
24
25 column of Table 3. Some of the differences noted are as follows. The one
26
27 recommendation in the checklist from the Society for Maternal-Fetal Medicine was
28
29 supported from its own clinical series article.[16, 24] The recommendation from the
30
31 bundle for prophylactic negative pressure wound therapy to reduce surgical site
32
33 infection at a hospital in New South Wales, Australia was not supported by any
34
35 recommendations in Table 2.[25] We observed that evidence-rated recommendations
36
37 supported the majority of the content in the checklist from Abdelmalek et al. These
38
39 included to notify anesthesiology providers, have resources available to accommodate
40
41 increased weight (e.g., operating room equipment, blood pressure cuffs), give
42
43 prophylactic anticoagulation (though dose adjustments not specified), and have a
44
45 lactation consultation.[26] However, content such as delay in staple removal or
46
47 adjustments in postpartum pain management were not found in other evidence-rated
48
49 recommendations in Table 2.
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Principal Findings

In our scoping review of the peripartum management of obesity, we found seven articles with evidence-rated recommendations. The articles included national guidelines from the FIGO (n=11 recommendations), United States (n=6 recommendations), United Kingdom (n=13 recommendations), and Canada (n=9 recommendations). The majority of the levels of evidence were second or third tier (Level 2 from GRADE, Level II or III from Canadian Task Force on Preventive Health Care, or Grade B or C from US Preventive Services Task Force). The recommendation that was of the highest grade (Strong, Level 1 or Grade A) was antibiotic prophylaxis for cesarean delivery,[14, 20] yet these recommendations apply to persons of all weights. A higher dosage of preoperative antibiotics for cesarean delivery also had the highest grade in one article[19] as well as subcutaneous tissue closure.[9, 20] We noted that 13 recommendations were based on expert opinion, or the lowest level of evidence. We noted that the majority of these recommendations would be considered “low-risk” interventions such as lactation and anesthesia consults and developing a system or clinical care pathway for persons with obesity. Other expert opinion recommendations might be considered in the labor management for all persons depending on the clinical situation (e.g., intravenous access, fetal heart rate monitoring, IUPC use).

Although we did not find directly opposing recommendations, there were subtle differences in some of the recommendations including criteria for anesthesia consults and antibiotic dosing. There is considerable debate over appropriate prophylactic dosing of antibiotics for cesarean delivery in persons with obesity given that pharmacokinetic

1
2
3 studies suggest improved or similar tissue concentrations with adjusted dosing,[31-34]
4
5 whereas a study comparing clinical outcomes such as surgical site infections did not
6
7 demonstrate significant differences when comparing standard vs. higher doses of
8
9 antibiotics.[35] The variations in recommendations may reflect the uncertainty of
10
11 whether to reach a physiological target vs. a clinical outcome.
12
13

14
15 We found that the recommendation for prophylactic negative pressure therapy in one
16
17 tool contradicted the Royal College of Obstetricians and Gynaecologists'
18
19 recommendation regarding this practice ("There is a lack of good-quality evidence to
20
21 recommend the routine use of negative pressure dressing therapy...").[20] We
22
23 acknowledge the content in the tools may be unique to a site depending on available
24
25 resources at the time of peripartum care as well as historical practice patterns, cost,
26
27 ease of use, and risk/benefit ratio to maternal and fetal health. In the tools we reviewed,
28
29 language such as "consider" or "anticipate" suggests that a concrete recommendation is
30
31 not available and care needs to be individualized.
32
33
34
35

36 **Strengths and limitations in relation to other studies**

37
38 Other authors have published summaries of clinical guidelines, similar to the ones we
39
40 identified. For example, a systematic review of guidelines available worldwide for the
41
42 management of obesity in pregnancy found 32 clinical practice guidelines covering the
43
44 domains of preconception care, care during pregnancy, diet and exercise during
45
46 pregnancy, care immediately before, during and after delivery, and postpartum care.[36]
47
48 For delivery and postpartum care, those authors identified the following
49
50 recommendations: (1) obesity alone not an indication for induction of labor, (2) early
51
52 establishment of venous access during labor for women with a BMI > 40 kg/m², (3)
53
54
55
56
57
58
59
60

1
2
3 allowing for a longer 1st stage of labor before performing a cesarean delivery for labor
4
5 arrest, and (4) active management of the 3rd stage of labor. Recommendations
6
7 pertaining to cesarean delivery included: (1) obesity alone not an indication for elective
8
9 cesarean delivery, (2) need for adequate staffing and equipment for maternal weight >
10
11 120 kg, (3) suturing subcutaneous tissue if > 2 cm of depth, (4) use of mechanical
12
13 thromboprophylaxis before and after cesarean delivery, and (5) weight-based dosing of
14
15 medication used to prevent VTE. Lastly, they also identified recommendations for
16
17 breastfeeding support and lactation consultants. These recommendations were similar
18
19 to the ones we identified from national guidelines in our scoping review.[9, 19, 20]
20
21
22
23
24 Several of the evidence-rated recommendations in Table 2 supported the content in the
25
26 11 tools we identified. However, we also found content not supported by evidence-rated
27
28 recommendations such as a peripherally inserted catheter for difficult intravenous
29
30 access and delayed staple removal. We identified a randomized controlled non-
31
32 inferiority trial of early (post-operative day 3) or delayed (between post-operative days 7
33
34 and 10) staple removal for transverse skin incisions in persons with a BMI \geq 30
35
36 kg/m².^[37] Although the study was stopped prior to reaching the targeted sample size,
37
38 the occurrence of superficial wound dehiscence was 15.2% in the early and 11.5% in
39
40 the delayed group (RR 1.3, 95% CI 0.7-2.4) and there were no other differences in the
41
42 secondary outcomes of seroma, hematoma, surgical site infection, or pain scores
43
44 among the two groups. Since the available evidence regarding timing of staple removal
45
46 is limited, other clinical and non-clinical characteristics such as provider and patient
47
48 preference likely contribute to decisions about staple removal timing.
49
50
51
52
53

54 **Strengths and limitations of this study**

55
56
57
58
59
60

We acknowledge several limitations to our study. We may not have identified all articles with evidence-rated recommendations, especially since our search ended in December 2020 and more recent articles were not identified. However, our search of available published literature was thorough including a search of appropriate web sites. Sites may have practical implementation tools that they use in the short- or long-term, but they may not be published or available in a more public domain. We identified clinical guidelines from other countries including Ireland and Australia,[38, 39] but they were not included in this review because they were not accompanied by evidence-rated recommendations. Although topics such as contraception and postpartum weight management are important in the postpartum care of persons with obesity, they were not specifically addressed in this review, which pertained to peripartum care in the immediate postpartum period. Obesity was typically defined according to a BMI ≥ 30.0 kg/m², but in many instances the timing of the BMI was not provided (e.g., pre-pregnancy vs. at delivery). Some recommendations were specific to a particular BMI cut-off, but others pertained to obesity, in general, without specifying a BMI. Lastly, we did not include recommendations that were intended for patient education only in this review.

Meaning of the study

Based on this scoping review, we propose the following key content for a peripartum checklist or toolkit in Table 4. This content is based on evidence ratings and ease of implementation. In summary, persons with obesity are at high risk for morbidity and mortality, with an abundance of risk occurring during the peripartum period. Few guidelines exist for the care of these persons and the evidence to support care is

1
2
3 limited. Thus, there is a need for high quality studies encompassing peripartum
4
5 interventions.
6
7

8 Table 4: Proposed key content for a peripartum checklist or toolkit for persons with obesity
9

Content	Examples
Provider discussion on labor induction, delivery route, and labor management	Allow for longer labor Difficulties in fetal heart rate monitoring
Expert consultations	Anesthesiologists Lactation consultants
Prophylaxis for cesarean delivery	Mechanical devices for VTE prophylaxis Higher dose of antibiotic before delivery depending on BMI Higher dose of anticoagulant after delivery depending on BMI
Wound management	Close subcutaneous tissue without drains or wound therapy

31 Conclusion

32
33 The recommendations for peripartum care for persons with obesity are based on limited
34 evidence and few practical tools for implementation exist. Future work should focus on
35 developing practical tools based on high quality studies.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributorship statement

MK designed the study protocol. LCO completed the database search of potential articles. MK, IC, JMP, AP, and PT reviewed abstracts, decided on inclusion and exclusion criteria, and reviewed the full-text of included articles. All authors contributed to the synthesis of results. All authors acknowledged approval of the final version for publication.

Competing interests

The authors have no competing interests to report.

Ethics approval statement

Ethics approval was not required since the study was a review of previously published articles.

Funding

There are no financial support resources to report.

Data sharing

The protocol is available for review at <https://doi.org/10.18131/g3-gyms-ww23>. A full list of the sources and search strategies is outlined in Appendix A.

REFERENCES

1. Ogden, C.L., et al., Prevalence of childhood and adult obesity in the United States, 2011-2012. *JAMA*, 2014. 311(8): p. 806-14.
2. Hales, C.M., et al., Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief*, 2017(288): p. 1-8.
3. Moore Simas, T.A., et al., Efforts needed to provide Institute of Medicine-recommended guidelines for gestational weight gain. *Obstet Gynecol*, 2010. 115(4): p. 777-83.
4. Bodnar, L.M., et al., Severe obesity, gestational weight gain, and adverse birth outcomes. *Am J Clin Nutr*, 2010. 91(6): p. 1642-8.
5. Deputy, N.P., A.J. Sharma, and S.Y. Kim, Gestational Weight Gain - United States, 2012 and 2013. *MMWR Morb Mortal Wkly Rep*, 2015. 64(43): p. 1215-20.
6. Gunatilake, R.P. and J.H. Perlow, Obesity and pregnancy: clinical management of the obese gravida. *Am J Obstet Gynecol*, 2011. 204: p. 106-19.
7. Marshall, N.E., et al., Maternal superobesity and perinatal outcomes. *Am J Obstet Gynecol*, 2012. 206(5): p. 417 e1-6.
8. Knight M, N.M., Tuffnell D, Shakespeare J, Kenyon S, Kurinczuk JJ (Eds.), *Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-2015*. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2017. 2017.
9. ACOG Practice Bulletin No 156: Obesity in Pregnancy. *Obstet Gynecol*, 2015. 126(6): p. e112-e126.
10. National Institute for Health and Care Excellence Clinical Guidelines. *Intrapartum care for women with existing medical conditions or obstetric complications and their babies*. London, 2019.
11. BERNSTEIN PS, COMBS CA, Shields LE, Clark SL, Eppes CS. The development and implementation of checklists in obstetrics. *Am J Obstet Gynecol* 2017;217:B2-B6.
12. Tricco, A.C., et al., PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*, 2018. 169(7): p. 467-473.
13. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
14. McAuliffe, F.M., et al., Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: A FIGO (International Federation of Gynecology and Obstetrics) guideline. *Int J Gynaecol Obstet*, 2020. 151 Suppl 1: p. 16-36.
15. Guyatt, G.H., et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336(7650): p. 924-6.
16. PACHECO LD, SAADE G, METZ TD. Society for Maternal-Fetal Medicine Consult Series #51: Thromboembolism prophylaxis for cesarean delivery. *Am J Obstet Gynecol* 2020;223:B11-B17.
17. van Schalkwyk, J. and N. Van Eyk, No. 247-Antibiotic Prophylaxis in Obstetric Procedures. *J Obstet Gynaecol Can*, 2017. 39(9): p. e293-e299.

18. Canadian Task Force on Preventive Health, C., New grades for recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ*, 2003. 169(3): p. 207-8.
19. Maxwell, C., et al., Guideline No. 392-Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care. *J Obstet Gynaecol Can*, 2019. 41(11): p. 1660-1675.
20. Denison, F.C., et al., Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72. *BJOG*, 2019. 126(3): p. e62-e106.
21. Royal College of Obstetricians and Gynaecologists. Developing a Green-top Guideline: Guidance for developers. London: RCOG, 2020.
22. RCOG. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. April 2015.
23. Grade Definitions. U.S. Preventive Services Task Force. October 2018. Available at <https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions>
24. COMBS CA. Society for Maternal-Fetal Medicine Special Statement: Checklist for thromboembolism prophylaxis after cesarean delivery. *Am J Obstet Gynecol* 2020;223:B22-B23.
25. Bolte, M., et al., Reducing surgical site infections post-caesarean section in an Australian hospital, using a bundled care approach. *Infect Dis Health*, 2020. 25(3): p. 158-167.
26. Abdelmalek, M.Z., S. Guest, and C. Maxwell, Team Planning in Obstetrical Care for Women With Obesity. *J Obstet Gynaecol Can*, 2019. 41(3): p. 338-343.
27. University of New Mexico School of Medicine. Standard operating procedure-guideline class 3 obesity and pregnancy. 2020. Available from: <http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf> [cited 2021 4.1.2021].
28. Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg>.
29. Obesity in pregnancy guidelines. 2020 [cited 2021 4.1.2021]; Available from: <https://www.northdevonhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf>
30. Antenatal management of obesity. 2018 [cited 2021 4.1.2021]; Available from: www.spectrumhealth.org/mfm/protocol-obesity.
31. Kram, J.J.F., et al., Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? *Eur J Obstet Gynecol Reprod Biol*, 2017. 210: p. 334-341.
32. Young, O.M., et al., Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. *Am J Obstet Gynecol*, 2015. 213(4): p. 541 e1-7.
33. Maggio, L., et al., Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. *Obstet Gynecol*, 2015. 125(5): p. 1205-1210.
34. Grupper, M., et al., Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. *J Clin Pharmacol*, 2017. 57(6): p. 712-719.


- 1
- 2
- 3
- 4 35. Ahmadzia, H.K., et al., Obstetric Surgical Site Infections: 2 Grams Compared
- 5 With 3 Grams of Cefazolin in Morbidly Obese Women. *Obstet Gynecol*, 2015.
- 6 126(4): p. 708-715.
- 7 36. Simon, A., et al., Guidelines for the management of pregnant women with
- 8 obesity: A systematic review. *Obes Rev*, 2020. 21(3): p. e12972.
- 9 37. Nuthalapaty, F.S., et al., A randomized controlled trial of early versus delayed
- 10 skin staple removal following caesarean section in the obese patient. *J Obstet*
- 11 *Gynaecol Can*, 2013. 35(5): p. 426-433.
- 12 38. Institute of Obstetricians and Gynaecologists Royal College of Physicians of
- 13 Ireland. Obesity and Pregnancy Clinical Practice Guideline. Guideline No.2 June
- 14 2011, revised June 2013.
- 15 39. The Australian and New Zealand College of Obstetricians and Gynaecologists.
- 16 C-Obs 49 Management of Obesity in Pregnancy. 2013.
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 Figure 1: PRISMA flow diagram for study selection.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



PRISMA Flow Diagram



Examples for exclusion:

^a Only study protocol or abstract available

^b Intervention may have occurred during prenatal care or postpartum, but not during delivery

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Appendix A Search Strategy

PubMed MEDLINE

Guidelines search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient[tiab] OR Parturients[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab]) AND (Toolkit[tiab] OR toolkits[tiab] OR Guideline[tiab] OR guidelines[tiab] OR Recommend*[tiab] OR Checklist[tiab] OR checklists[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR "Best practice"[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR "Network Meta-Analysis"[Mesh] OR systematic[ti] OR scoping[ti] OR meta-analy*[ti])

Interventions search

("Obesity"[Mesh] OR Obesity[tiab] OR Obese[tiab] OR Superobesity[tiab]) AND ("Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Pregnant Women"[Mesh] OR "Delivery, Obstetric"[Mesh] OR "Peripartum Period"[Mesh] OR "Perinatal Care"[Mesh] OR Pregnancy[tiab] OR Pregnancies[tiab] OR Pregnant[tiab] OR Parturition[tiab] OR Parturient*[tiab] OR Peripartum[tiab] OR Perinatal[tiab] OR Prenatal[tiab] OR Antenatal[tiab] OR Antepartum[tiab] OR Intrapartum[tiab] OR Postpartum[tiab] OR Cesarean[tiab])

AND (Toolkit*[tiab] OR Guideline*[tiab] OR Recommend*[tiab] OR Checklist*[tiab] OR consensus[tiab] OR Evidence-based[tiab] OR Best practice*[tiab] OR "Clinical management" [tiab] OR "Anesthetic management"[tiab] OR anesthesia[tiab] OR anaesthesia[tiab] OR Standards[tiab] OR "Guideline" [Publication Type] OR "Practice Guidelines as Topic"[Mesh] OR "Practice Guideline" [Publication Type] OR "Early Medical Intervention"[Mesh] OR "Patient Education as Topic"[Mesh] OR "Health Education"[Mesh] OR intervention*[tiab] OR therapy[subheading] OR therapy[tiab] OR treatment[tiab])

AND

("Case-Control Studies"[Mesh:noexp] OR "retrospective studies"[mesh:noexp] OR "Control Groups"[Mesh:noexp] OR (case[TIAB] AND control[TIAB]) OR (cases[TIAB] AND controls[TIAB]) OR (cases[TIAB] AND controlled[TIAB]) OR (case[TIAB] AND comparison*[TIAB]) OR (cases[TIAB] AND comparison*[TIAB]) OR "control

group"[TIAB] OR "control groups"[TIAB] OR cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] OR randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh]))

Filters used for the interventions search:

http://libguides.sph.uth.tmc.edu/search_filters/pubmed_filters

<https://work.cochrane.org/pubmed>

Embase (embase.com)

Guidelines search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'evidence based practice'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR Toolkit*:ti,ab OR Guideline*:ti,ab OR Recommend*:ti,ab OR Checklist*:ti,ab OR consensus:ti,ab OR Evidence-based:ti,ab OR 'Best practice*':ti,ab OR "Clinical management":ti,ab OR "Anesthetic management":ti,ab OR anesthesia:ti,ab OR anaesthesia:ti,ab OR Standards:ti,ab OR systematic:ti OR scoping:ti OR meta-analy*:ti

Interventions search

'obesity'/exp OR obesity:ti,ab OR superobesity:ti,ab

AND

'pregnancy'/exp OR 'pregnancy disorder'/de OR 'high risk pregnancy'/exp OR 'labor complication'/exp OR 'multiple pregnancy'/exp OR 'obstetric emergency'/exp OR 'placenta disorder'/exp OR 'pregnancy complication'/exp OR 'pregnancy disorders of endocrine origin'/exp OR 'pregnancy toxemia'/exp OR 'prolonged pregnancy'/exp OR 'puerperal disorder'/exp OR 'pregnant woman'/exp OR 'obstetric delivery'/exp OR 'perinatal period'/exp OR 'perinatal care'/exp OR Pregnancy:ti,ab OR Pregnancies:ti,ab OR Pregnant:ti,ab OR Parturition:ti,ab OR Parturient*:ti,ab OR Peripartum:ti,ab OR Perinatal:ti,ab OR Prenatal:ti,ab OR Antenatal:ti,ab OR Antepartum:ti,ab OR Intrapartum:ti,ab OR Postpartum:ti,ab OR Cesarean:ti,ab

AND

'guideline'/exp OR 'checklist'/exp OR 'consensus development'/exp OR 'practice guideline'/exp OR 'standards'/exp OR 'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR toolkit*:ti,ab OR guideline*:ti,ab OR recommend*:ti,ab OR checklist*:ti,ab OR consensus:ti,ab OR 'evidence based':ti,ab OR 'best practice':ti,ab OR 'clinical management':ti,ab OR 'anesthetic management':ti,ab OR standards:ti,ab OR 'intervention study'/exp OR 'patient education'/exp OR 'health education'/exp OR 'therapy'/exp OR intervention*:ti,ab OR therapy:ti,ab OR treatment:ti,ab

AND

'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind procedure':de OR (random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* NEAR/1 blind* OR assign* OR allocat* OR volunteer*):de,ab,ti OR 'clinical article'/exp OR 'controlled study'/exp OR 'major clinical study'/exp OR 'prospective study'/exp OR 'cohort analysis'/exp OR 'cohort':ti,ab OR 'compared':ti,ab OR 'groups':ti,ab OR 'case control':ti,ab OR 'multivariate':ti,ab

Filters:

<https://guides.library.harvard.edu/c.php?g=309982&p=2079546>

<https://work.cochrane.org/embase>

CENTRAL: Cochrane Register of Controlled Trials

Guidelines and intervention search

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 (Obesity OR Obese OR Superobesity):ti,ab,kw

- 1
2
3 #3 #1 OR #2
4
5 #4 MeSH descriptor: [Pregnancy] explode all trees
6
7 #5 MeSH descriptor: [Pregnancy Complications] explode all trees
8
9 #6 MeSH descriptor: [Pregnant Women] explode all trees
10
11 #7 MeSH descriptor: [Delivery, Obstetric] explode all trees
12
13 #8 MeSH descriptor: [Peripartum Period] explode all trees
14
15 #9 MeSH descriptor: [Perinatal Care] explode all trees
16
17 #10 Pregnancy:ti,kw,ab OR Pregnancies:ti,kw,ab OR Pregnant:ti,kw,ab OR
18 Parturition:ti,kw,ab OR Parturient*:ti,kw,ab OR Peripartum:ti,kw,ab OR Perinatal:ti,kw,ab
19 OR Prenatal:ti,kw,ab OR Antenatal:ti,kw,ab OR Antepartum:ti,kw,ab OR
20 Intrapartum:ti,kw,ab OR Postpartum:ti,kw,ab OR Cesarean:ti,kw,ab
21
22 #11 {OR #4-#10}
23
24 #12 Toolkit*:ti,kw,ab OR Guideline*:ti,kw,ab OR Recommend*:ti,kw,ab OR
25 Checklist*:ti,kw,ab OR consensus:ti,kw,ab OR Evidence-based:ti,kw,ab OR Best
26 practice*:ti,kw,ab OR “Clinical management”:ti,kw,ab OR “Anesthetic
27 management”:ti,kw,ab OR anesthesia:ti,kw,ab OR anaesthesia:ti,kw,ab OR
28 Standards:ti,kw,ab
29
30
31 #13 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
32
33 #14 systematic:ti OR scoping:ti OR meta-analy*:ti
34
35 #15 #12 OR #13 OR #14
36
37 #16 #3 AND #11 AND #15
38
39 #17 MeSH descriptor: [Early Medical Intervention] explode all trees
40
41 #18 MeSH descriptor: [Patient Education as Topic] explode all trees
42
43 #19 MeSH descriptor: [Health Education] explode all trees
44
45 #20 MeSH descriptor: [Therapeutics] explode all trees
46
47 #21 intervention*:ti,kw,ab OR therapy:ti,kw,ab OR treatment:ti,kw,ab
48
49 #22 {OR #17-#21}
50
51 #23 #3 AND #11 AND #22
52
53 #24 #16 OR #23
54
55
-

CINAHL (EbscoHost)**Guidelines search**

((MH "Obesity") OR (MH "Obesity, Morbid")) OR TI (Obesity OR Obese OR Superobesity) OR AB (Obesity OR Obese OR Superobesity)

AND

((MH "Pregnancy+") OR (MH "Pregnancy, Multiple+") OR (MH "Pregnancy Trimesters+") OR (MH "Pregnancy, Unplanned") OR (MH "Pregnancy, Unwanted") OR (MH "Expectant Mothers") OR (MH "Pregnancy Complications+") OR (MH "Obstetric Care+") OR (MH "Postnatal Care+") OR (MH "Postnatal Period+")) OR TI (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean) OR AB (Perinatal OR Pregnancy OR Pregnancies OR Pregnant OR Parturition OR Parturient* OR Peripartum OR Prenatal OR Antenatal OR Antepartum OR Intrapartum OR Postpartum OR Cesarean)

AND

((MH "Practice Guidelines") OR (MH "Meta Analysis") OR (MH "Meta Synthesis")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards) OR TI (systematic OR scoping OR meta-analy*)

Interventions search

((MH "Early Intervention") OR (MH "Patient Education+") OR (MH "Health Education+") OR (MH "Pregnancy Outcomes") OR (MH "Treatment Outcomes+")) OR TI (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment) OR AB (Toolkit* OR Guideline* OR Recommend* OR Checklist* OR consensus OR Evidence-based OR Best practice* OR "Clinical management" OR "Anesthetic management" OR anesthesia OR anaesthesia OR Standards OR "Early Medical Intervention" OR "Patient Education as Topic" OR "Health Education" OR intervention* OR therapy OR treatment)

AND

(MH "Prospective Studies") OR TI (cohort OR longitudinal OR prospective OR retrospective) OR AB (cohort OR longitudinal OR prospective OR retrospective) OR ((MH "Random Assignment") or (MH "Random Sample+") or (MH "Crossover Design") or (MH "Clinical Trials+") or (MH "Comparative Studies") or (MH "Control (Research)+") or (MH "Control Group") or (MH "Factorial Design") or (MH "Quasi-Experimental Studies+") or (MH "Placebos") or (MH "Meta Analysis") or (MH "Sample Size") or (MH "Research, Nursing") or (MH "Research Question") or (MH "Research Methodology+") or (MH "Evaluation Research+") or (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") or (MH "Nursing Practice, Research-Based") or (MH "Solomon Four-Group Design") or (MH "One-Shot Case Study") or (MH "Pretest-Posttest Design+") or (MH "Static Group Comparison") or (MH "Study Design") or (MH "Clinical Research+")) or (clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or meta?analy* or systematic review* or blind* or mask* or trial*))

Clinicaltrials.gov

Keyword searches included pregnancy and obesity.

Google searches

Recognizing that guidelines, toolkits, and checklists are often not published in the journal literature, we supplemented the guidelines search strategy with Google searches. To ensure more precision we limited the results to .org and .gov domains.

Searches were run in Google for "obesity pregnancy guideline" with the following limits:

1. Words in page title only
2. Words in URL only
3. .org domain
4. .gov domain
5. .gov.uk domain
6. .org.uk domain
7. .gov.au domain
8. .org.au domain

On the assumption that the Google search algorithm pushes the most relevant results to the top, one reviewer (MK) screened the first four pages of results for each search, looking for guidelines and checklists not already included in our previous search results. For the identified sites, the other authors (PT, AP, IC, JP) also voted to include or exclude the sites. The most recent search was conducted in April 2021.

Title	Year	Source or Site	Tool type	Content
Obesity in Pregnancy [1] ^a	8.2021	Department of Health in Queensland, AU Guideline: Obesity and pregnancy (including post bariatric surgery) (health.qld.gov.au)	Flow Chart	<p>Intrapartum</p> <p>If BMI > 40 kg/m²</p> <ul style="list-style-type: none"> Early assessment of IV access Recommend continuous fetal monitoring <p>If prophylactic antibiotics, consider higher dosage</p> <p>Active third stage management</p> <p>Surveillance for shoulder dystocia/PPH</p> <p>Postpartum</p> <ul style="list-style-type: none"> Surveillance for airway compromise Early mobilisation Assess risk of VTE and consider thromboprophylaxis Additional support for breastfeeding
Class 3 Obesity and Pregnancy [2]	7.2020	University of New Mexico Department of Obstetrics and Gynecology http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%20%20Obesity%20and%20Pregnancy.pdf	Standard operating procedure-guideline	<p>Intrapartum</p> <ul style="list-style-type: none"> No clear evidence for routine IOL solely for class 3 obesity Higher morbidity with TOLAC compared to repeat CD in this specific population Consider repeat CD in this population Alert team of increased risk of shoulder dystocia and PPH Anesthesia evaluation before admission, or early in admission Pneumatic compression stockings during labor Continuous fetal and uterine monitoring in labor Avoid use of wound vacs or drains <p>Postpartum</p> <ul style="list-style-type: none"> Low-molecular weight heparin for thromboprophylaxis for 5-6 days postpartum Weight based prophylaxis is better option Breast feeding encouraged due to higher risks of difficulties Lactation counseling Consider lactation consulting Incentive spirometry Early ambulation Avoid early hospital discharge
Obesity in Pregnancy [3]	4.2018	Alaska Native Medical Center https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf	Guideline	<p>Intrapartum</p> <ul style="list-style-type: none"> Use appropriate sized blood pressure cuff Anticipate higher dose of oxytocin for induction or augmentation of labor Consider placement of prophylactic epidural catheter <p>If BMI > 40 kg/m²</p> <ul style="list-style-type: none"> Consider early IUPC and FSE

36/bmjopen-2022-061430 on 15 September 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

36/bmjopen-2022-061433 Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

				<p>If BMI > 50 kg/m² Anesthesia consult on admission Consider additional use of IV famotidine and/or metoclopramide Anticipate higher rate of failed regional anesthesia Anticipate difficult airway (have videolaryngoscope available, have laryngeal mask airway available, have emergency cricothyroidotomy kit available)</p> <p>If Cesarean delivery Bariatric surgery should not be considered an indication for CD Anticipate greater time from incision to delivery Pfannenstiel incision carries less risk of infection and dehiscence than midline incision Consider retracting panniculus cephalad (or caudad) with tape or large "loban" drape Consider self-retaining retractor, extra-long instruments Close subcutaneous layer (34% decrease in wound disruption) Subcutaneous drains may be associated with a higher risk of infection Consider closure with polydioxanone (PDS) Consider Smead-Jones "mass closure" If staples used for skin closure, do not remove until 7-10 days postoperatively for a vertical incision and 5 days for a Pfannenstiel Increase dose of prophylactic cefazolin to 3 g IV before incision if BMI > 40 kg/m² Panniculectomy at the time of CD increases complications Early ambulation Intermittent pneumatic compression devices Consider using bariatric bed with frame and trapeze for mobility postoperatively Anticoagulation if 1 major or 2 minor ASCP risk factors for VTE Enoxaparin 40mg every 12 hours for BMI < 50 kg/m², 60 mg every 12 hours for BMI > 50 kg/m² or weight based dosing (e.g., enoxaparin 0.5 mg/kg every 12 hours)</p>
Obesity in Pregnancy Guideline [4]	9.2020	National Health System Northern Devon Healthcare United Kingdom https://www.northdevo	Care Pathway	<p>Intrapartum All blood pressure measurements should be taken using the appropriate size arm cuff. Complete a manual handling risk assessment to ensure the correct equipment is available and used</p>

		<p>nhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf</p>		<p>Measure and fit TED anti-embolism stockings. Consider calf compression device for all women with BMI ≥ 40. Assess pressure areas and maintain skin integrity. Consider ultrasound scan to confirm fetal presentation. Be alert to increased risk of shoulder dystocia. The duty anaesthetist and duty obstetric registrar should be informed when a woman with a BMI ≥ 40 is admitted to labour ward. Women with a BMI ≥ 40 should have IV access early in labour with "FBC and group and save taken". For women with a BMI ≥ 40, prophylactic omeprazole should be administered as per prescription. Raised BMI alone is not an indication for continuous fetal monitoring in labour. Postpartum All women with a BMI ≥ 35 should be recommended to have active management of the third stage of labour Women with a BMI ≥ 30 should be encouraged to mobilise as early as practicable following childbirth to reduce the risk of thromboembolism. TED stockings or calf compression devices to be worn throughout hospital stay regardless of mode of delivery for women with BMI ≥ 35. Assess wound and observe for signs of dehiscence.</p>
<p>Obesity in Pregnancy, Labour and Puerperium [5]</p>	<p>2019</p>	<p>University Hospitals of Leicester NHS Trust United Kingdom Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk)</p>	<p>Guideline</p>	<p>Intrapartum: Assessment of tissue viability by completing "Waterlow Risk Assessment Form"; if value > 10 then inspect skin daily via "BEST SHOT" guidance (also postpartum) Notify OR staff on admission if weight > 140 kg Postpartum: Early mobilization Use compression stocking if ≥ 2 risk factors VTE prophylaxis for 7 days if ≥ 1 risk factors If BMI ≥ 40: Early IV access Consider early epidural Experienced obstetrician (\geq ST6) to perform CD or "rotational instrumental delivery" Active management of 3rd stage Consider IV syntocinon instead of IM route</p>

36/bmjopen-2022-01-133001 For peer review only. See https://www.bmj.com/ for all copyright and related notices. Downloaded from https://bmjopen.bmj.com/ on April 20, 2023 by guest. Protected by copyright.

36/bmjopen-2022-014800 on 19 September 2022. Downloaded from <http://bmjopen.bmj.com/> on 19 April 2024 by guest. Protected by copyright.

				VTE prophylaxis regardless of delivery route Consider increased dose of antibiotic prophylaxis
Obesity Medicine Management of obesity in women's health care. Chapter 19: Checklists for Care: Care Maps for Pregnancy in the Obese Gravida [6]	2017	United States	CareMap	Intrapartum Obtain clear fetal heart tracing and uterine contraction assessment Place SCD Early consultation with anesthesia Confirm adequate equipment for anesthesia, labor and delivery, and operating room Discuss/plan for the following: delivery route, skin cleansing/preparation, antibiotic dosing for CD (consider 3g cefazolin if weight > 120 kg), postpartum VTE prophylaxis (SCD, LMWH), early ambulation, perineal laceration or incision care, address medical comorbidities, medication adjustments Immediate postpartum VTE prophylaxis Early ambulation Anticoagulation (if indicated) Lactation referral
Supporting a Plus-Size Pregnancy: A Checklist for Healthcare Providers [7]	2019	United States NIH/NICHD, National Child and Maternal Health Education Program NIH Pub.Number: 19-HD-8100 https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf	Checklist	Ensure availability of appropriate birthing beds and monitoring/other equipment to care for plus-size patients (e.g., large chairs and wheelchairs, larger blood pressure cuffs). Assess appropriateness of gurneys and staffing plans and revise as needed (e.g., get motorized lifts for gurneys, increase staff to assist with moving the patient). Consider consulting with an anesthesia service, especially for patients with obstructive sleep apnea, in case the need for a surgical delivery arises. Consider early epidural catheter placement, and discuss the risks and benefits with the patient. Consider allowing a longer first stage of labor before performing cesarean delivery for labor arrest. Work with your patient to create a birthing plan, including pain management methods. Work with your patient to create a breastfeeding plan and help her get lactation support/consultation, if needed.
Antenatal Management of Obesity [8]	2018	Spectrum Health Medical Group Michigan, United States	Protocol	Anesthesia consult if BMI > 60 Prophylactic antibiotics "Azithro + Ancel" (3g if >120kg) Delivery timing 39-40 weeks

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		www.spectrumhealth.org/mfm/protocol-obesity		Consider wound vac placement post op if Class III obesity with risk factors (DM, chorio) or BMI > 60 Postop prophylactic lovenox while inpatient for class I and II obesity with risk factors, >= class III regardless of risk factors
--	--	--	--	---

Appendix B: Title, year of publication, source of recommendations, and content topic for tools for the peripartum management of obesity identified from searches of Google Scholar.

^a During original Google scholar search on 4.1.21, the Queensland Clinical Guideline for “Obesity in pregnancy” was published in 2015. When the manuscript was updated for publication, a new version of the guideline was published in 8.2021 and therefore the most recent guideline was used for this manuscript since the prior link was no longer available.

IOL induction of labor

CD or CS cesarean delivery

IV intravenous

BMI body mass index


PPH postpartum hemorrhage

VTE venous thromboembolism

TOLAC trial of labor after cesarean

IUPC intrauterine pressure catheter

FSE fetal scalp electrode



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

PDS polydioxanone

ACCP American College of Chest Physicians

TED thrombo-embolus deterrent

OR operating room

NIBP non-invasive blood pressure

BP blood pressure

NB neuraxial blockade

LMWH low molecular weight heparin

DM diabetes

For peer review only

References:

- [1] Queensland Clinical Guidelines. Obesity and pregnancy (including post bariatric surgery). Guideline No. MN21.14-V6-R26. Queensland Health. 2021. Available from: <http://www.health.qld.gov.au/qcg>. Accessed 9/24/21.
- [2] University of New Mexico School of Medicine. Standard operating procedure-guideline class 3 obesity and pregnancy. 2020. Available from: <http://unmobgyn.pbworks.com/w/file/attach/140915307/Class%203%20Obesity%20and%20Pregnancy.pdf>. Accessed 4/1/21.
- [3] Obesity in pregnancy - ANMC guideline Alaska Native Medical Center. Available from: <https://anmc.org/wp-content/uploads/ClinicalGuidelinesMaster/Obesity.pdf>. Accessed 4/1/21.
- [4] Obesity in pregnancy guidelines. 2020. Available from: <https://www.northdevonhealth.nhs.uk/wp-content/uploads/2018/06/Obesity-in-Pregnancy-Guideline.pdf>. Accessed 4/1/21.
- [5] Obesity in pregnancy, labour and the puerperium. University Hospitals of Leicester NHS Trust 2019. Available from: Microsoft Word - Obesity in Pregnancy Labour 18 7 19 (leicestershospitals.nhs.uk). Accessed 4/1/21.
- [6] Silverman RK. Obesity Medicine: Management of Obesity in Women's Health Care 1ed: McGraw-Hill Education; 2017.
- [7] Supporting a plus-size pregnancy: a checklist for healthcare providers NIH Pub.Number: 19-HD-8100: Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2019. Available from: https://www.nichd.nih.gov/sites/default/files/2019-11/Healthcare_Provider_Checklist.pdf. Accessed 4/1/21.
- [8] Antenatal management of obesity. 2018 Available from: www.spectrumhealth.org/mfm/protocol-obesity. Accessed 4/1/21.

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	3
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	Cover letter
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	4
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	4, Appendix A
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix A
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	4
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	5
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	5



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	5
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	5, figure 1
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	6, Table 1,2,Appendix B
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	6-7
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	6-7
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	8
Limitations	20	Discuss the limitations of the scoping review process.	10
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	9, Table 3
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Title page

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: 10.7326/M18-0850.



St. Michael's

Inspired Care.
Inspiring Science.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>